{"custom_id": "alendronic acid-Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\n"}]}}
{"custom_id": "Ketoprofen-Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-insomnia-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\n"}]}}
{"custom_id": "alendronic acid-Efavirenz-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Efavirenz\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Efavirenz-constipated-oxybutynin\n"}]}}
{"custom_id": "Carvedilol-Efavirenz-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Efavirenz\nDRUG 2 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 3 NAME: Lamivudine\nDRUG 3 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-High blood pressure-Efavirenz\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Efavirenz-gastric inflammation-Lamivudine\n"}]}}
{"custom_id": "Norfloxacin-Zolpidem-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Norfloxacin\nDRUG 1 BACKGROUND INFORMATION: Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.\nNorfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.\nIt was patented in 1977 and approved for medical use in 1983.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: vincristine\nDRUG 3 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Norfloxacin-folate deficiency-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-Adenopathy-vincristine\n"}]}}
{"custom_id": "Metolazone-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metolazone\nDRUG 1 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metolazone-Adenopathy-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "Ketorolac-Ondansetron-Trazodone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Ondansetron\nDRUG 2 BACKGROUND INFORMATION: Ondansetron, a potent antiemetic utilized to mitigate nausea and emesis associated with chemotherapy, radiation, migraine, and surgical procedures, exerts its pharmacological action as a selective serotonin 5-HT3 receptor antagonist. Absence of affinity for dopaminergic and muscarinic acetylcholine receptors precludes extrapyramidal side effects such as akathisia. Administered via oral, intravenous, or intramuscular routes, ondansetron's pharmacokinetic profile is characterized by hepatic metabolism and renal excretion. Adverse effects frequently reported encompass gastrointestinal dysmotility manifesting as diarrhea or constipation, central nervous system manifestations including headache and somnolence, and dermal pruritus, with more severe toxicities including QT interval prolongation on electrocardiographic assessment and anaphylaxis. Although the teratogenic risk is minimal, comprehensive teratological data in gravid populations remain insufficient. Recognized on the WHO's List of Essential Medicines, ondansetron is extensively prescribed, highlighting its clinical utility and incorporation into treatment protocols, with significant utilization confirmed by its high prescription frequency in the United States.\n\nDRUG 3 NAME: Trazodone\nDRUG 3 BACKGROUND INFORMATION: Trazodone is an antidepressant medication used to treat major depressive disorder, anxiety disorders, and insomnia. It is a phenylpiperazine compound of the serotonin antagonist and reuptake inhibitor (SARI) class. The medication is taken orally.\nCommon side effects include dry mouth, feeling faint, vomiting, and headache. More serious side effects may include suicide, mania, irregular heart rate, and pathologically prolonged erections. It is unclear if use during pregnancy or breastfeeding is safe.  Trazodone also has sedating effects.\nTrazodone was approved for medical use in the United States in 1981. It is available as a generic medication. In 2022, it was the eighteenth most commonly prescribed medication in the United States, with more than 27 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-Adenopathy-Ondansetron\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ondansetron-hepatic neoplasia-Trazodone\n"}]}}
{"custom_id": "Oxaprozin-Sildenafil-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Oxaprozin\nDRUG 1 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 3 NAME: Zaleplon\nDRUG 3 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Oxaprozin-gastric inflammation-Sildenafil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sildenafil-apoplexy-Zaleplon\n"}]}}
{"custom_id": "Ketorolac-Duloxetine-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 3 NAME: desvenlafaxine\nDRUG 3 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-back injury-Duloxetine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Duloxetine-Adenopathy-desvenlafaxine\n"}]}}
{"custom_id": "Lidocaine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-trigeminal neuralgia-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "Citalopram-oxybutynin-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 3 NAME: Pirbuterol\nDRUG 3 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-oxybutynin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): oxybutynin-apoplexy-Pirbuterol\n"}]}}
{"custom_id": "Naproxen-Lamotrigine-Amiloride-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Amiloride\nDRUG 3 BACKGROUND INFORMATION: Amiloride, marketed as Midamor, is a potassium-sparing diuretic frequently employed adjunctively with thiazide or loop diuretics for managing hypertension and edematous states associated with heart failure or hepatic cirrhosis, administered orally. Its pharmacodynamic profile is characterized by inhibition of epithelial sodium channels (ENaC) within the late distal convoluted tubule, connecting tubule, and collecting duct, culminating in attenuated sodium reabsorption and concurrent preservation of potassium levels, manifested as reduced urinary potassium excretion. The pharmacokinetic parameters indicate a two-hour onset of action with a duration spanning approximately 24 hours. Adverse effects predominantly encompass hyperkalemia, pertinent to individuals with renal impairment, advanced age, or diabetes mellitus, along with gastrointestinal disturbances, dermatological reactions, and cephalalgia.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-weight gain-Amiloride\n"}]}}
{"custom_id": "Diazepam-Ibuprofen-desvenlafaxine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: desvenlafaxine\nDRUG 3 BACKGROUND INFORMATION: Desvenlafaxine, a potent SNRI antidepressant clinically designated for major depressive disorder, exerts its pharmacological effects via inhibition of presynaptic serotonin and norepinephrine transporters, thereby augmenting synaptic concentrations of these neurotransmitters. Administered orally, its therapeutic efficacy necessitates periodic reevaluation to ascertain continued benefit relative to its progenitor compound, venlafaxine, with mixed comparative results reported. Adverse event profiles include central nervous system perturbations such as dizziness and somnolence, autonomic dysregulation manifesting as hyperhidrosis and hypertension, gastrointestinal disturbances like constipation, and sexual dysfunction, alongside the potential for eliciting severe psychiatric and systemic crises such as serotonin syndrome, manic episodes, and hemorrhagic events. The abrupt cessation of desvenlafaxine is contraindicated due to a significant risk of withdrawal syndrome. Teratogenic and lactational safety remains inadequately characterized. Despite its prevalent prescription status in the United States, regulatory approval within the European context was not attained, underscoring variances in regional pharmaco-therapeutic standards.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Diazepam-gastric inflammation-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-bleeding Vaginal-desvenlafaxine\n"}]}}
{"custom_id": "Ketoprofen-oxybutynin-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketoprofen\nDRUG 1 BACKGROUND INFORMATION: Ketoprofen is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID) with analgesic and antipyretic effects. It acts by inhibiting the body's production of prostaglandin.\nIt was patented in 1967 and approved for medical use in 1980.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 3 NAME: Pirbuterol\nDRUG 3 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketoprofen-gastric inflammation-oxybutynin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): oxybutynin-apoplexy-Pirbuterol\n"}]}}
{"custom_id": "Bumetanide-vincristine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Bumetanide\nDRUG 1 BACKGROUND INFORMATION: Bumetanide, a potent loop diuretic prominently utilized for amelioration of edema due to congestive heart failure, hepatic cirrhosis, or renal insufficiency, operates by robustly inhibiting the sodium-potassium-chloride cotransporter in the thick ascending limb of Henle's loop, consequently attenuating sodium reabsorption, enhancing natriuresis and diuresis. Although not the antihypertensive of first choice, its rapid onset post-oral or parenteral administration\u2014manifesting within one hour with a diuretic effect persisting approximately six hours\u2014renders it efficacious in scenarios refractory to alternative agents. The pharmacodynamic profile necessitates vigilant monitoring for electrolyte imbalances, notably hypokalemia, and adverse nephrological manifestations, in addition to more rare ototoxic and hematologic complications. Routine laboratory evaluations, including serum electrolytes and renal function tests, are advocated during therapy. Bumetanide's teratogenic risks remain inconclusive, advising prudence during gestation and lactation. The extensive clinical utilization underscores its inclusion in the World Health Organization\u2019s compendium of essential medicines, despite its preferential status as a secondary option in hypertension management.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 3 NAME: Torasemide\nDRUG 3 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Bumetanide-neumonia-vincristine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): vincristine-drug toxicity NOS-Torasemide\n"}]}}
{"custom_id": "acetazolamide-Famotidine-Lamivudine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Famotidine\nDRUG 2 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 3 NAME: Lamivudine\nDRUG 3 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-Back Ache-Famotidine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamivudine\n"}]}}
{"custom_id": "Amlodipine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Amlodipine-erythema-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "indometacin-oxybutynin-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: oxybutynin\nDRUG 2 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 3 NAME: Zaleplon\nDRUG 3 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): indometacin-apoplexy-oxybutynin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): oxybutynin-apoplexy-Zaleplon\n"}]}}
{"custom_id": "Candesartan-Desloratadine-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 3 NAME: Darunavir\nDRUG 3 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Candesartan-apoplexy-Desloratadine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Desloratadine-acute pancreatitis-Darunavir\n"}]}}
{"custom_id": "alendronic acid-Ibuprofen-Propofol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Propofol\nDRUG 3 BACKGROUND INFORMATION: Propofol, a 2,6-diisopropylphenol compound, serves as a cornerstone intravenous agent for induction and maintenance of general anesthesia, leveraging its rapid onset and rapid clearance pharmacokinetics for broad clinical applicability, including peri-procedural sedation and the management of refractory status epilepticus. Administered as a sterile, lipid-based emulsion incorporating soy-based triglycerides and egg-derived lecithin, this formulation's distinct milky appearance underscores its non-aqueous solubility requisites. Propofol elicits unconsciousness expeditiously upon bolus administration and facilitates smooth maintenance via infusion strategies, attributed to its GABA_A receptor agonism which potentiates inhibitory neurotransmission and culminates in reduced synaptic excitability. Its clinical advantage is underscored by an attenuated profile of postoperative sedation-related adverse effects, namely residual drowsiness, nausea, and vomiting, rivalling alternative anesthetic agents. As a critical agent on the WHO List of Essential Medicines, its utility spans diagnostic, surgical, and emergency care contexts, although administration mandates diligent monitoring due to potential for hemodynamic and respiratory modulation.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-gastric inflammation-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-dysarthria-Propofol\n"}]}}
{"custom_id": "Methylphenidate-Megestrol-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Megestrol\nDRUG 2 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-gastric inflammation-Megestrol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Megestrol-loss of weight-Desloratadine\n"}]}}
{"custom_id": "Alprazolam-Benazepril-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-gastric inflammation-Benazepril\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Benazepril-apoplexy-Terazosin\n"}]}}
{"custom_id": "Triazolam-Rosiglitazone-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Triazolam\nDRUG 1 BACKGROUND INFORMATION: Triazolam, sold under the brand name Halcion among others, is a central nervous system (CNS) depressant tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepine (BZD) derivatives. It possesses pharmacological properties similar to those of other benzodiazepines, but it is generally only used as a sedative to treat severe insomnia. In addition to the hypnotic properties, triazolam's amnesic, anxiolytic, sedative, anticonvulsant, and muscle relaxant properties are pronounced as well.\nTriazolam was initially patented in 1970 and went on sale in the United States in 1982. In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Triazolam-neumonia-Rosiglitazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Rosiglitazone-Adenopathy-Bimatoprost\n"}]}}
{"custom_id": "Rofecoxib-Telmisartan-Cinacalcet-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG 3 NAME: Cinacalcet\nDRUG 3 BACKGROUND INFORMATION: Cinacalcet, sold under the brand name Sensipar among others, is a medication used to treat primary hyperparathyroidism, tertiary hyperparathyroidism and parathyroid carcinoma. Cinacalcet acts as a calcimimetic (i.e., it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues.\nThe most common side effects include nausea and vomiting.\nCinacalcet was approved in the United States in March 2004, and in the European Union in October 2004. It was the first allosteric G protein-coupled receptor modulator to enter the pharmaceutical market. In 2013, cinacalcet was the 76th most prescribed medicine in the United States.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-cholecystitis-Telmisartan\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Telmisartan-dysarthria-Cinacalcet\n"}]}}
{"custom_id": "Diazepam-Gemfibrozil-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Sildenafil\nDRUG 3 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Diazepam-cholecystitis-Gemfibrozil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Gemfibrozil-erythema-Sildenafil\n"}]}}
{"custom_id": "Cetirizine-Sildenafil-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cetirizine\nDRUG 1 BACKGROUND INFORMATION: Cetirizine, a second-generation selective H1 antihistaminergic agent, is primarily administered orally for the amelioration of allergic rhinitis, dermatitis, and urticaria, exerting its pharmacodynamic effects predominantly extracellularly, thereby minimizing central nervous system penetration and consequent sedative effects typical of first-generation antihistamines such as diphenhydramine. Its clinical onset transpires within thirty minutes, maintaining therapeutic efficacy for approximately 24 hours with an adverse effect profile that includes somnolence, xerostomia, cephalalgia, and abdominal discomfort, albeit with a diminished proclivity for sedation compared to its first-generation counterparts due to its peripheral selectivity. Amongst its second-generation analogs, cetirizine exhibits a comparatively higher incidence of somnolence vis-\u00e0-vis fexofenadine and loratadine. It is contraindicated in lactation but permissible during gestation and extends its utility to pediatric cohorts with caution advised regarding potential somnolence. Being generically available and included in the World Health Organization's List of Essential Medicines, cetirizine\u2019s broad prescriptive prevalence, as evidenced by over 13 million US prescriptions in 2022, underscores its efficacy and widespread utilitarian value in allergy management.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 3 NAME: Zaleplon\nDRUG 3 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cetirizine-erythema-Sildenafil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sildenafil-apoplexy-Zaleplon\n"}]}}
{"custom_id": "Doxazosin-Metoprolol-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-Dyspnea exertional-Bimatoprost\n"}]}}
{"custom_id": "Cimetidine-Labetalol-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Labetalol\nDRUG 2 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-back injury-Labetalol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\n"}]}}
{"custom_id": "Labetalol-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Labetalol\nDRUG 1 BACKGROUND INFORMATION: Labetalol is a medication used to treat high blood pressure and in long term management of angina. This includes essential hypertension, hypertensive emergencies, and hypertension of pregnancy. In essential hypertension it is generally less preferred than a number of other blood pressure medications. It can be given by mouth or by injection into a vein.\nCommon side effects include low blood pressure with standing, dizziness, feeling tired, and nausea. Serious side effects may include low blood pressure, liver problems, heart failure, and bronchospasm. Use appears safe in the latter part of pregnancy and it is not expected to cause problems during breastfeeding. It works by blocking the activation of \u03b2- and \u03b1-adrenergic receptors.\nLabetalol was patented in 1966 and came into medical use in 1977. It is available as a generic medication. In 2022, it was the 215th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Pirbuterol\nDRUG 3 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Labetalol-apoplexy-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-erythema-Pirbuterol\n"}]}}
{"custom_id": "Citalopram-Zolpidem-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: vincristine\nDRUG 3 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Citalopram-Adenopathy-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-Adenopathy-vincristine\n"}]}}
{"custom_id": "Lamotrigine-Dexpramipexole-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 3 NAME: Trimethoprim\nDRUG 3 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-gastric inflammation-Dexpramipexole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-weight gain-Trimethoprim\n"}]}}
{"custom_id": "Lamotrigine-Metolazone-Dexpramipexole-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamotrigine\nDRUG 1 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 2 NAME: Metolazone\nDRUG 2 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 3 NAME: Dexpramipexole\nDRUG 3 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-still birth-Metolazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metolazone-loss of weight-Dexpramipexole\n"}]}}
{"custom_id": "Naproxen-Zolpidem-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-Perindopril\n"}]}}
{"custom_id": "Ketorolac-Duloxetine-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 3 NAME: Sorafenib\nDRUG 3 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-back injury-Duloxetine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Duloxetine-apoplexy-Sorafenib\n"}]}}
{"custom_id": "Zafirlukast-Duloxetine-Sorafenib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Zafirlukast\nDRUG 1 BACKGROUND INFORMATION: Zafirlukast, an orally bioavailable leukotriene receptor antagonist, targets the cysteinyl leukotriene receptor subtypes CysLT1, thereby attenuating leukotriene-mediated bronchoconstriction, microvascular permeability, and airway inflammation pivotal in the asthma pathophysiology. While generally well tolerated, adverse reactions include cephalalgia and gastrointestinal disturbances; however, hepatotoxicity such as fulminant hepatic failure and eosinophilic granulomatosis with polyangiitis have been sporadically reported, though the latter lacks a definitive causal linkage. Zafirlukast undergoes extensive hepatic biotransformation via the cytochrome P450 2C9 isoenzyme, with consequential inhibition of CYP3A4, delineating a potential for pharmacokinetic drug-drug interactions. Polymorphisms in LTC4 synthase and cytochrome P450 2C9 may modulate individual response variability to this pharmacotherapy.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 3 NAME: Sorafenib\nDRUG 3 BACKGROUND INFORMATION: Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Zafirlukast-loss of weight-Duloxetine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Duloxetine-apoplexy-Sorafenib\n"}]}}
{"custom_id": "chlortalidone-Sildenafil-Zaleplon-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: chlortalidone\nDRUG 1 BACKGROUND INFORMATION: Chlortalidone, a thiazide-like sulfonamide diuretic, is predominantly prescribed for antihypertensive therapy and states of edema associated with heart failure, hepatic cirrhosis, and nephrotic syndrome, as well as for managing nephrogenic diabetes insipidus and renal tubular acidosis. Its pharmacodynamic efficacy stems from modulating renal sodium and water excretion, thereby affecting volume and pressure homeostasis; the precise mechanistic pathways, however, remain partially elucidated. Its pharmacokinetic profile reveals oral bioavailability with an onset of diuresis within approximately three hours, sustaining therapeutic effects for up to 72 hours. Comparative studies suggest chlortalidone's superior cardiovascular outcome efficacy over hydrochlorothiazide in long-term stroke and myocardial infarction prophylaxis, despite a contentious spectrum of adverse effect profiles, including hypokalemia, hyponatremia, hyperglycemia, orthostatic hypotension, and reduced erectile function, alongside rarer occurrences of gout, hypomagnesemia, hypercalcemia, and hypersensitivity reactions. Pregnancy use, although possible, is approached with caution due to alternative preferred therapeutics. As part of the WHO's essential medicines list, chlortalidone remains a critical agent in hypertension management, widely available as a cost-effective generic, reflecting its substantial utilization in clinical practice.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 3 NAME: Zaleplon\nDRUG 3 BACKGROUND INFORMATION: Zaleplon, sold under the brand name Sonata among others, is a sedative and hypnotic which is used to treat insomnia. It is a nonbenzodiazepine or Z-drug of the pyrazolopyrimidine class. It was developed by King Pharmaceuticals and approved for medical use in the United States in 1999.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): chlortalidone-loss of weight-Sildenafil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sildenafil-apoplexy-Zaleplon\n"}]}}
{"custom_id": "Naproxen-Minoxidil-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Minoxidil\nDRUG 2 BACKGROUND INFORMATION: Minoxidil  is a medication used for the treatment of high blood pressure and pattern hair loss. It is an antihypertensive and a vasodilator. It is available as a generic medication by prescription in oral tablet form and over-the-counter as a topical liquid or foam.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastroenteritis viral-Minoxidil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Minoxidil-thrombocytopenia-Perindopril\n"}]}}
{"custom_id": "Naproxen-Carvedilol-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Carvedilol\nDRUG 2 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 3 NAME: Metolazone\nDRUG 3 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-Adenopathy-Carvedilol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-erythema-Metolazone\n"}]}}
{"custom_id": "Aciclovir-Citalopram-Ranolazine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Aciclovir\nDRUG 1 BACKGROUND INFORMATION: Aciclovir, an antiviral guanosine analogue, exhibits its therapeutic efficacy predominantly by inhibiting viral DNA polymerase through its metabolization to aciclovir triphosphate, resulting in the cessation of herpesvirus DNA elongation across Herpes Simplex Virus, varicella-zoster, and CMV prophylaxis post-transplantation. Administerable orally, topically, or intravenously, its pharmacokinetic profile necessitates careful consideration in patients with compromised renal or hepatic function due to potential nephrotoxicity and thrombocytopenia. While demonstrating an acceptable safety margin during gestation and lactation, adverse events such as gastrointestinal discomfort and diarrhea are common. Its inclusion in the WHO's Essential Medicines list underscores its global pivotal role in antiviral therapy, with its generic accessibility enhancing universal healthcare implementation.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: Ranolazine\nDRUG 3 BACKGROUND INFORMATION: Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.\nCommon side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.\nRanolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Aciclovir-methaemoglobinaemia-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-bursitis-Ranolazine\n"}]}}
{"custom_id": "Famotidine-Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-Adenopathy-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\n"}]}}
{"custom_id": "Naproxen-Furosemide-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Furosemide\nDRUG 2 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 3 NAME: Oxaprozin\nDRUG 3 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-adenomyosis-Furosemide\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Furosemide-gastric inflammation-Oxaprozin\n"}]}}
{"custom_id": "Methylphenidate-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Methylphenidate\nDRUG 1 BACKGROUND INFORMATION: Methylphenidate, a CNS stimulant within the phenethylamine and piperidine classes, exerts therapeutic effects in ADHD and narcolepsy predominantly through the inhibition of presynaptic dopamine and norepinephrine transporters, thereby augmenting synaptic monoamine concentrations. Its pharmacodynamics establish a clinical efficacy for enhancing executive functions such as attentional control, inhibitory processes, working memory, and emotional regulation, albeit with a slightly reduced efficacy compared to amphetamines. Pharmacokinetically, methylphenidate is amenable to both oral and transdermal administration with formulation-dependent pharmacokinetics dictating therapeutic windows. Adverse effects span neuropsychiatric and autonomic domains, including, but not limited to, sympathomimetic manifestations such as tachycardia, euphoria, anorexia, and insomnia, while withdrawal is typified by dysphoric and neurovegetative symptoms. Methylphenidate's status as a high-frequency prescription medication is underscored by its extensive dispensation, ranking as the 32nd most prescribed medication in the U.S. as of 2022, available in both branded and generic forms.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Methylphenidate-cholecystitis-Ziprasidone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\n"}]}}
{"custom_id": "Duloxetine-Desloratadine-Darunavir-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Duloxetine\nDRUG 1 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 3 NAME: Darunavir\nDRUG 3 BACKGROUND INFORMATION: Darunavir (DRV) is an antiretroviral protease inhibitor utilized primarily for the therapeutic regimen of HIV/AIDS, necessitating concomitant administration with pharmacokinetic enhancers such as ritonavir or cobicistat to potentiate systemic bioavailability. DRV performs its mechanism of action through the inhibition of the HIV-1 protease enzyme, thus impairing viral polyprotein processing and subsequent viral maturation. Clinical administration can be post-exposure prophylaxis, particularly following potential occupational or non-occupational exposure. Adverse effects manifest variably from gastrointestinal disturbances to severe dermatological reactions including toxic epidermal necrolysis, with hepatotoxicity noted as a critical consideration. While teratogenic data remains limited, current clinical evidence suggests relative neonatal safety. Commercial formulations include combination therapies like darunavir/cobicistat (Prezcobix, Rezolsta) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide (Symtuza), presenting enhanced compliance through reduced dosing complexity.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Duloxetine-gastric inflammation-Desloratadine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Desloratadine-acute pancreatitis-Darunavir\n"}]}}
{"custom_id": "Tramadol-Telmisartan-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Telmisartan\nDRUG 2 BACKGROUND INFORMATION: Telmisartan, an angiotensin II receptor antagonist, is efficacious in the modulation of hypertension and heart failure via oral administration. It operates by antagonizing the angiotensin II AT1 receptor, thereby mitigating vasoconstrictive, aldosterone-secreting, and proliferative actions of angiotensin II. Clinically, it significantly reduces systemic vascular resistance and subsequently lowers blood pressure. While the therapeutic index is favorable, adverse effects such as upper respiratory tract infections, gastrointestinal disturbances, and lumbar discomfort are noted, with more severe complications including renal impairment, hypotension, and angioedema. Telmisartan is contraindicated during pregnancy due to potential teratogenicity and is not advised during lactation. It is frequently formulated in combination with diuretics or calcium channel blockers, like hydrochlorothiazide, cilnidipine, and amlodipine, to enhance antihypertensive efficacy.\n\nDRUG 3 NAME: solifenacin\nDRUG 3 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Tramadol-cholecystitis-Telmisartan\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Telmisartan-dysarthria-solifenacin\n"}]}}
{"custom_id": "Celecoxib-Oxaprozin-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Oxaprozin\nDRUG 2 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG 3 NAME: Sildenafil\nDRUG 3 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-Adenopathy-Oxaprozin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Oxaprozin-gastric inflammation-Sildenafil\n"}]}}
{"custom_id": "Naproxen-Lamotrigine-Zolpidem-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Zolpidem\nDRUG 3 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-Cystitis Interstitial-Zolpidem\n"}]}}
{"custom_id": "Doxazosin-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Pirbuterol\nDRUG 3 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-erythema-Pirbuterol\n"}]}}
{"custom_id": "Rofecoxib-Zolpidem-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Rofecoxib\nDRUG 1 BACKGROUND INFORMATION: Rofecoxib, a COX-2-selective NSAID, was originally indicated for various arthritic conditions, acute pain, migraines, and dysmenorrhea, until its market withdrawal in 2004 due to augmented cardiovascular (CV) risks, particularly myocardial infarction and cerebrovascular accidents, linked to prolonged high-dosage utilization. The drug's comparative pharmacodynamic profile achieved specificity towards cyclooxygenase-2 isoform inhibition, theoretically minimizing gastrointestinal mucosal compromise yet correlating with increased thromboembolic events, a risk shared by nonselective NSAIDs per longitudinal clinical evaluation. Despite its market retraction, an orphan drug designation was granted to Tremeau Pharmaceuticals in 2017 for rofecoxib (TRM-201) targeting hemophilic arthropathy (HA), a condition necessitating analgesic intervention devoid of NSAID-induced platelet inhibition or opioid dependency, thereby providing a unique therapeutic niche given the absence of other approved agents for HA in the U.S., a population at risk due to recurrent hemarthroses and its degenerative sequelae.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Rofecoxib-Adenopathy-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-abnormal ECG-Bimatoprost\n"}]}}
{"custom_id": "nevirapine-Ofloxacin-Imatinib-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: nevirapine\nDRUG 1 BACKGROUND INFORMATION: Nevirapine (NVP), sold under the brand name Viramune among others, is a medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medications. It may be used to prevent mother to child spread during birth but is not recommended following other exposures. It is taken by mouth.\nCommon side effects include rash, headache, nausea, feeling tired, and liver problems. The liver problems and skin rash may be severe and should be checked for during the first few months of treatment. It appears to be safe for use during pregnancy. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and works by blocking the function of reverse transcriptase.\nNevirapine was approved for medical use in the United States in 1996. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG 2 NAME: Ofloxacin\nDRUG 2 BACKGROUND INFORMATION: Ofloxacin, a member of the fluoroquinolone class, functions as a DNA synthesis inhibitor by targeting bacterial DNA gyrase and topoisomerase IV, making it efficacious against an array of bacterial pathogens. Clinically, ofloxacin is administered orally or intravenously for conditions such as pneumonia, cellulitis, urinary tract infections, prostatitis, and plague, with combination protocols extending its utility to multidrug-resistant tuberculosis. Furthermore, ophthalmic formulations address superficial ocular infections, while otic solutions are effective for otitis media complicated by tympanic membrane perforation. However, its pharmacotherapeutic profile is burdened by adverse effects like gastrointestinal disturbances, CNS involvement manifesting as headaches or psychosis, and peripheral neuropathy leading to limb paresthesia or tendon rupture, making it contraindicated during pregnancy. Despite these side effects, ofloxacin maintains a pivotal role in antimicrobial therapy, underscored by its inclusion in the World Health Organization's List of Essential Medicines amid widespread prescription as a generic formulation.\n\nDRUG 3 NAME: Imatinib\nDRUG 3 BACKGROUND INFORMATION: Imatinib, branded as Gleevec and Glivec, is an orally administered ATP-competitive small molecule inhibitor with specificity against a range of tyrosine kinases, including CSF1R, BCR-ABL, c-KIT, FLT3, and PDGFR-\u03b2, making it a pivotal treatment in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), alongside applications in gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome. Its mechanism involves the inhibition of the fusion protein Bcr-Abl tyrosine kinase, thereby impeding proliferative signaling cascades and inducing apoptosis in neoplastic cells. Notable adverse reactions encompass gastrointestinal disturbances, musculoskeletal discomfort, cephalalgia, dermatological manifestations, with more severe toxicities such as edema, myelosuppression, hemorrhagic events, hepatotoxicity, and cardiac dysfunction; moreover, teratogenic potential mandates cautious use during gestation. Imatinib's recognition by the World Health Organization as essential highlights its critical role in oncologic pharmacopeia, with a generic formulation introduced into the UK market in 2017.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): nevirapine-anogenital warts-Ofloxacin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ofloxacin-weight gain-Imatinib\n"}]}}
{"custom_id": "Lidocaine-Metoprolol-Fulvestrant-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lidocaine\nDRUG 1 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Fulvestrant\nDRUG 3 BACKGROUND INFORMATION: Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. It is given by injection into a muscle.\nFulvestrant is a selective estrogen receptor degrader (SERD) and was first-in-class to be approved. It works by binding to the estrogen receptor and destabilizing it, causing the cell's normal protein degradation processes to destroy it.\nFulvestrant was approved for medical use in the United States in 2002.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-cholecystitis-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-abdominal pain upper-Fulvestrant\n"}]}}
{"custom_id": "Carvedilol-Dexpramipexole-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 3 NAME: Ticlopidine\nDRUG 3 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-gastric inflammation-Dexpramipexole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-hyperglycaemia-Ticlopidine\n"}]}}
{"custom_id": "Efavirenz-Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Efavirenz\nDRUG 1 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Efavirenz-gastric inflammation-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\n"}]}}
{"custom_id": "Lamivudine-Metoprolol-Pirbuterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Lamivudine\nDRUG 1 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Pirbuterol\nDRUG 3 BACKGROUND INFORMATION: Pirbuterol (trade name Maxair) is a short-acting \u03b22 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.\nIt was patented in 1971 and came into medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-erythema-Pirbuterol\n"}]}}
{"custom_id": "Ketorolac-Duloxetine-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ketorolac\nDRUG 1 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 2 NAME: Duloxetine\nDRUG 2 BACKGROUND INFORMATION: Duloxetine, a pharmacological agent classified as a serotonin\u2013norepinephrine reuptake inhibitor (SNRI), exhibits efficacy in ameliorating symptoms associated with major depressive disorder, generalized anxiety disorder, obsessive\u2013compulsive disorder, fibromyalgia, neuropathic pain, and central sensitization by modulating the synaptic reuptake mechanisms of neurotransmitters. While the exact molecular pathways underlying its therapeutic anxiolytic and antidepressant effects remain elusive, duloxetine's engagement with serotonergic and noradrenergic systems is hypothesized to play a critical role. Adverse events frequently encountered include xerostomia, nausea, asthenia, vertigo, psychomotor agitation, sexual dysfunction, and hyperhidrosis, while the drug also poses risks of severe outcomes such as heightened suicidality, serotonin toxicity, manic episodes, hepatotoxicity, and teratogenic effects if administered during late gestation. Additionally, abrupt cessation of duloxetine may precipitate antidepressant discontinuation syndrome. Marketed as both branded and generic formulations, duloxetine figures prominently in psychopharmacology, ranking among the most prescribed medications with significant prevalence, underscoring its entrenched role in contemporary clinical practice.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-back injury-Duloxetine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Duloxetine-gastric inflammation-Desloratadine\n"}]}}
{"custom_id": "Norfloxacin-Zolpidem-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Norfloxacin\nDRUG 1 BACKGROUND INFORMATION: Norfloxacin, sold under the brand name Noroxin among others, is an antibiotic that belongs to the class of fluoroquinolone antibiotics. It is used to treat urinary tract infections, gynecological infections, inflammation of the prostate gland, gonorrhea and bladder infection. Eye drops were approved for use in children older than one year of age.\nNorfloxacin is associated with a number of rare serious adverse reactions as well as spontaneous tendon ruptures and irreversible peripheral neuropathy. Tendon problems may manifest long after therapy had been completed and in severe cases may result in lifelong disabilities.\nIt was patented in 1977 and approved for medical use in 1983.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: solifenacin\nDRUG 3 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Norfloxacin-folate deficiency-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-solifenacin\n"}]}}
{"custom_id": "Metronidazole-vincristine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 3 NAME: Torasemide\nDRUG 3 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metronidazole-Acute Respiratory Distress Syndrome-vincristine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): vincristine-drug toxicity NOS-Torasemide\n"}]}}
{"custom_id": "Furosemide-Zolpidem-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Furosemide-fracture nonunion-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-Perindopril\n"}]}}
{"custom_id": "Furosemide-Zolpidem-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: solifenacin\nDRUG 3 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Furosemide-fracture nonunion-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-loss of weight-solifenacin\n"}]}}
{"custom_id": "Temazepam-Megestrol-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Temazepam\nDRUG 1 BACKGROUND INFORMATION: Temazepam is a benzodiazepine class hypnotic agent indicated primarily for the management of severe insomnia, characterized by its rapid oral absorption with clinically significant hypnotic and anxiolytic actions initiating within 30 minutes and persisting for approximately eight hours. The pharmacodynamic efficacy is mediated via positive allosteric modulation of the GABA-A receptor, enhancing GABAergic neurotransmission and inducing sedative-hypnotic outcomes. Despite its historical utilization, the prescription prevalence has diminished, supplanted by z-drugs and certain atypical antidepressants due to a more favorable side effect profile. Temazepam\u2019s pharmacokinetic and safety concerns include side effects such as ataxia, cognitive dysfunction, and in severe cases, can escalate to hallucinations, hypotension, and potential respiratory depression, particularly when co-administered with CNS depressants like alcohol or opioids. The withdrawal syndrome poses a significant risk upon rapid cessation following prolonged use. Teratogenic concerns contraindicate use during pregnancy and lactation. Despite its historical ubiquity as evidenced by over two million prescriptions in 2021, the clinical positioning of temazepam now leans towards refractory insomnia cases where alternative pharmacotherapy has been deemed inadequate.\n\nDRUG 2 NAME: Megestrol\nDRUG 2 BACKGROUND INFORMATION: Megestrol (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name) is a progestin of the 17\u03b1-hydroxyprogesterone group which was, until recently, never marketed or used clinically. It is now used for treatments of disease-related weight loss, endometrial cancer, and breast cancer. Its acylated derivative megestrol acetate is also a progestogen, which, in contrast to megestrol itself, has been extensively used as a pharmaceutical drug.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Temazepam-cholecystitis-Megestrol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Megestrol-loss of weight-Desloratadine\n"}]}}
{"custom_id": "Risedronic acid-Zolpidem-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Risedronic acid\nDRUG 1 BACKGROUND INFORMATION: Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate. It slows down the cells which break down bone. It's used to treat or prevent osteoporosis, and treat Paget's disease of bone. It is taken by mouth.\nIt was patented in 1984 and approved for medical use in 1998.\n\nDRUG 2 NAME: Zolpidem\nDRUG 2 BACKGROUND INFORMATION: Zolpidem is a nonbenzodiazepine hypnotic agent, distinguished pharmacologically as an imidazopyridine and classified as a Z-drug, primarily indicated for the short-term amelioration of insomnia. Its therapeutic efficacy in decreasing sleep latency, quantified as approximately a 15-minute reduction in sleep onset, is attributed to its function as a positive allosteric modulator of the GABAA receptor, thereby potentiating inhibitory GABAergic transmission in the central nervous system by binding at sites akin to benzodiazepines. Pharmacokinetically, zolpidem exhibits a biphasic elimination with a half-life averaging 2 to 3 hours, extended in hepatic impairment, necessitating careful dose adjustments. Administered orally, it is formulated as immediate-release, extended-release, and sublingual tablets, with dosing typically post-behavioral interventions such as CBT-I and sleep hygiene practices. Adverse effect profiles include, but are not limited to, somnolence, cephalalgia, nausea, and potential neuropsychiatric disturbances like amnesia and visual/auditory hallucinations, warranting consideration of flumazenil antagonism in overdose scenarios albeit primarily managed with supportive measures. Zolpidem's controlled substance designation under Schedule IV in the US reflects its abuse potential, underscored by its high prescription frequency with over 9 million prescriptions annually, placing it as a prominent therapeutic option for sleep disorders.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Risedronic acid-erythema-Zolpidem\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Zolpidem-abnormal ECG-Bimatoprost\n"}]}}
{"custom_id": "Naproxen-Capecitabine-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Capecitabine\nDRUG 2 BACKGROUND INFORMATION: Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.\nCommon side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.\nCapecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-loss of weight-Capecitabine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Capecitabine-drug toxicity NOS-Desloratadine\n"}]}}
{"custom_id": "Etiracetam-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Etiracetam\nDRUG 1 BACKGROUND INFORMATION: Etiracetam is a chemical compound belonging to the racetam family, which was developed as a nootropic drug. It is racemic; its biologically active enantiomeric form is levetiracetam, now marketed as an antiepileptic drug.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Etiracetam-abnormal EEG-Ziprasidone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\n"}]}}
{"custom_id": "Haloperidol-Rosiglitazone-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: Rosiglitazone\nDRUG 2 BACKGROUND INFORMATION: Rosiglitazone is a thiazolidinedione-class pharmacologic agent that acts as a peroxisome proliferator-activated receptor gamma (PPAR\u03b3) agonist, facilitating enhanced insulin sensitivity in adipocytes. Despite demonstrating efficacy in glycemic modulation for Type 2 diabetes mellitus via its action on PPAR\u03b3, concerns regarding cardiovascular risk emerged, precipitating a precipitous decline in utilization post-2007 after meta-analytic data implicated it in myocardial infarction risk augmentation. This prompted the European Medicines Agency to recommend its market withdrawal due to an unfavorable risk-benefit profile, whereas the FDA, after imposing stringent prescription controls, eventually rescinded such requirements following re-evaluation of cardiovascular outcomes in subsequent trials. Rosiglitazone's commercial trajectory reflects contentious safety profiles, culminating in extensive litigation against GlaxoSmithKline, despite its continued availability in the U.S. under regulated conditions, contrasting with withdrawal from multiple international markets due to regulatory edicts.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Haloperidol-insulin dependent diabetes mellitus-Rosiglitazone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Rosiglitazone-Adenopathy-Bimatoprost\n"}]}}
{"custom_id": "Diazepam-Pyridostigmine-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Diazepam\nDRUG 1 BACKGROUND INFORMATION: Diazepam, a prototypical member of the benzodiazepine pharmacological class, functions primarily as an anxiolytic by potentiation of GABAergic neurotransmission, enhancing the binding affinity of gamma-aminobutyric acid (GABA) at the GABA_A receptor complex. It is employed in the management of a diverse array of conditions, including, but not limited to, generalized anxiety disorder, status epilepticus, alcohol withdrawal delirium, spasticity, insomnia, and restless legs syndrome, with additional utility in procedural amnesia induction. Diazepam exhibits versatile administration routes\u2014oral, rectal, intramuscular, intravenous, and intranasal, with IV administration eliciting rapid onset of action within 1-5 minutes and demonstrating a relatively short duration of clinical efficacy. Oral administration results in peak plasma concentrations within 15 to 60 minutes. While generally well-tolerated, its adverse effect profile includes CNS depression manifesting as sedation and impaired motor coordination, with rare, yet severe risks like respiratory depression, paradoxical excitation, and seizure exacerbation with chronic use. Chronic administration raises the risk of tolerance, physical dependence, and a withdrawal syndrome upon abrupt cessation; cognitive impairments post-discontinuation are well-documented. It is contraindicated in pregnancy and lactation due to teratogenic and neonatal withdrawal potential. Diazepam continues to be a mainstay therapeutic agent on the World Health Organization\u2019s List of Essential Medicines, despite its risk for abuse and dependency, underscoring the necessity for judicious prescribing practice.\n\nDRUG 2 NAME: Pyridostigmine\nDRUG 2 BACKGROUND INFORMATION: Pyridostigmine, a quaternary ammonium acetylcholinesterase inhibitor, augments synaptic acetylcholine concentrations by inhibiting its enzymatic hydrolysis, thus enhancing cholinergic transmission at neuromuscular junctions. Primarily indicated for the symptomatic management of myasthenia gravis and neurogenic bladder dysfunction, pyridostigmine also plays a pivotal role in reversing neuromuscular blockade induced by non-depolarizing agents, particularly when administered concomitantly with atropine to mitigate muscarinic side effects. Off-label, it addresses dysautonomia in certain variants of Postural Orthostatic Tachycardia Syndrome. Administered orally or via parenteral routes, it exhibits an onset of action at approximately 45 minutes with a pharmacodynamic tenure spanning up to four hours. Adverse effects manifest predominantly as gastrointestinal disturbances such as nausea and diarrhea, though hypotension, skeletal muscle weakness, and hypersensitivity reactions present significant risks. Its safety profile during gestation remains indeterminate. As an agent of the cholinergic pharmacotherapeutic class, pyridostigmine is enshrined in the World Health Organization's compendium of essential medications and is available in generic formulations.\n\nDRUG 3 NAME: Telithromycin\nDRUG 3 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Diazepam-Diplopia-Pyridostigmine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pyridostigmine-dysarthria-Telithromycin\n"}]}}
{"custom_id": "Tramadol-Ziprasidone-Desloratadine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Tramadol\nDRUG 1 BACKGROUND INFORMATION: Tramadol is an atypical analgesic integrating opioid and monoaminergic mechanisms, with dual action as a \u03bc-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), indicated for moderate to severe pain management. The immediate-release oral formulation facilitates rapid analgesic onset approximately within sixty minutes, and the drug is also administrable via parenteral routes. Metabolically, tramadol undergoes hepatic biotransformation to O-desmethyltramadol (desmetramadol), demonstrating enhanced \u03bc-receptor binding affinity. Adverse effects parallel opioid pharmacodynamics, encompassing gastrointestinal dysmotility resulting in constipation, pruritus, and emesis; with noteworthy risks of seizures, serotonergic toxicity, central nervous system depression, and dependency potential. Renal or hepatic impairments necessitate dose adjustments, while contraindications include pregnancy, lactation (although minimal risk after a solitary dose), and suicidality predispositions. Tramadol is frequently dispensed in combination with acetaminophen and is extensively available under multiple brand denominations and as a generic formulation.\n\nDRUG 2 NAME: Ziprasidone\nDRUG 2 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 3 NAME: Desloratadine\nDRUG 3 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Tramadol-erythema-Ziprasidone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\n"}]}}
{"custom_id": "Doxazosin-Metoprolol-Acitretin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Metoprolol\nDRUG 2 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 3 NAME: Acitretin\nDRUG 3 BACKGROUND INFORMATION: Acitretin, sold under the brand names Neotigason and Soriatane, is a second-generation retinoid. It is taken orally, and is typically used for psoriasis.\nAcitretin is an oral retinoid used in the treatment of severe resistant psoriasis. Because of the potential for problems and severe side effects it is generally used in only very severe cases of psoriasis that have been unresponsive to other treatments.  It binds to nuclear receptors that regulates gene transcription.  They induce keratinocyte differentiation and reduce epidermal hyperplasia, leading to the slowing of cell reproduction.  Acitretin is readily absorbed and widely distributed after oral administration.  A therapeutic effect occurs after two to four weeks or longer.\nPatients who have received the medication are advised against giving blood for at least three years due to the risk of birth defects.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-gastric inflammation-Metoprolol\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Metoprolol-loss of weight-Acitretin\n"}]}}
{"custom_id": "Alprazolam-Ciclopirox-hydroxychloroquine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Ciclopirox\nDRUG 2 BACKGROUND INFORMATION: Ciclopirox is a medication used for the treatment of moderate onychomycosis of fingernails and toenails, and for the treatment of seborrheic dermatitis.\nIn 2022, it was the 247th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: hydroxychloroquine\nDRUG 3 BACKGROUND INFORMATION: Hydroxychloroquine, chemically classified within the 4-aminoquinoline antimalarial pharmacophore, is primarily indicated for malaria prophylaxis and therapeutic intervention in chloroquine-sensitive endemic regions, while possessing secondary applications in autoimmune pathologies such as rheumatoid arthritis and lupus erythematosus, and hereditary porphyrias like porphyria cutanea tarda. Orally administered as hydroxychloroquine sulfate, its pharmacodynamics entail immunomodulation potentially via interference with lysosomal activity and autophagy processes. Adverse effects range from gastrointestinal disturbances and neuromuscular impairments to severe toxicities, including irreversible retinopathy, potentially through phototoxic damage, cardiovascular arrhythmias, possibly via QT interval prolongation, and hypersensitivity reactions. Despite teratogenic risks, its teratogenicity remains unsubstantiated, enabling cautious use in rheumatic conditions during gestation. Although initial studies erroneously posited an antiviral efficacy against SARS-CoV-2, subsequent rigorously controlled clinical trials delineated a lack of efficacy coupled with a propensity for adverse events, jeopardizing drug availability for FDA-approved conditions. Consequently, hydroxychloroquine's role in COVID-19 treatment is widely contraindicated, reaffirming its therapeutic utilization within its defined medicinal scope.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-arterial pressure NOS decreased-Ciclopirox\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ciclopirox-Adenopathy-hydroxychloroquine\n"}]}}
{"custom_id": "Candesartan-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Candesartan-gastric inflammation-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "folinic acid-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: folinic acid\nDRUG 1 BACKGROUND INFORMATION: Folinic acid, also known as leucovorin, is a medication used to decrease the toxic effects of methotrexate and pyrimethamine. It is also used in combination with 5-fluorouracil to treat colorectal cancer and pancreatic cancer, may be used to treat folate deficiency that results in anemia, and methanol poisoning. It is taken by mouth, injection into a muscle, or injection into a vein.\nSide effects may include trouble sleeping, allergic reactions, or fever. Use in pregnancy or breastfeeding is generally regarded as safe. When used for anemia it is recommended that pernicious anemia as a cause be ruled out first. Folinic acid is a form of folic acid that does not require activation by dihydrofolate reductase to be useful to the body.\nFolinic acid was first made in 1945. It is on the World Health Organization's List of Essential Medicines.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): folinic acid-abnormal ECG-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "Naproxen-alendronic acid-Efavirenz-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: alendronic acid\nDRUG 2 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 3 NAME: Efavirenz\nDRUG 3 BACKGROUND INFORMATION: Efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), exerts its antiretroviral efficacy by allosterically inhibiting the HIV-1 reverse transcriptase enzyme, thereby impeding viral DNA synthesis and subsequent viral replication. Typically administered orally, either as a monotherapy or in combination formulations such as efavirenz/emtricitabine/tenofovir, it constitutes a cornerstone in antiretroviral regimens aimed at both therapeutic management and post-exposure prophylaxis in cases of potential HIV transmission exposure, such as needlestick injuries. Despite its clinical efficacy, adverse events such as dermatological eruptions, including Stevens\u2013Johnson syndrome, and neuropsychiatric manifestations, encompassing depression and suicidal ideations, as well as hepatic and neurological disturbances, notably contraindicate its use during pregnancy due to potential teratogenicity. However, due to its clinical importance, evidenced by its inclusion in the World Health Organization's List of Essential Medicines, it remains widely available, including in generic formulations post-patent expiration.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-gastric inflammation-alendronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-Adenopathy-Efavirenz\n"}]}}
{"custom_id": "indometacin-vincristine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: indometacin\nDRUG 1 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 3 NAME: Torasemide\nDRUG 3 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): indometacin-Acute Respiratory Distress Syndrome-vincristine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): vincristine-drug toxicity NOS-Torasemide\n"}]}}
{"custom_id": "Amlodipine-Dexpramipexole-Ticlopidine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Amlodipine\nDRUG 1 BACKGROUND INFORMATION: Amlodipine, a dihydropyridine-type long-acting calcium channel antagonist, exerts its pharmacological action primarily through vasodilation by impeding calcium ion influx through L-type calcium channels in vascular smooth muscle, which ameliorates hypertension, coronary artery disease, and variant angina. Administered orally, its pharmacokinetic profile necessitates caution in hepatic impairment and geriatric populations, requiring dose modulation. Although the teratogenic risk during gestation or lactation remains indeterminate, its side effect profile encompasses peripheral edema, lethargy, gastrointestinal distress, and potential hypotension or myocardial infarction. This compound's significant therapeutic utility has merited its inclusion on the WHO Essential Medicines List and extensive global prescription prevalence while remaining generically accessible.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 3 NAME: Ticlopidine\nDRUG 3 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Amlodipine-Adenopathy-Dexpramipexole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-hyperglycaemia-Ticlopidine\n"}]}}
{"custom_id": "Candesartan-Lamivudine-Metoprolol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: Lamivudine\nDRUG 2 BACKGROUND INFORMATION: Lamivudine, or 3TC, is a nucleoside reverse transcriptase inhibitor with efficacy against HIV-1, HIV-2, and chronic hepatitis B virus. It functions by competitive inhibition of HIV reverse transcriptase and hepatitis B virus polymerase, disrupting viral DNA synthesis. Clinically, lamivudine is integral to combination antiretroviral therapy, often co-administered with agents such as zidovudine, dolutegravir, and abacavir, and forms part of post-exposure prophylactic regimens. It is available for oral administration as liquid or tablet formulations, maintaining therapeutic flexibility through its dosing independence from food intake. While generally well-tolerated, adverse effects can include gastrointestinal disturbances, cephalalgia, asthenia, and respiratory symptoms; however, clinicians must vigilantly monitor for hepatotoxicity, lactic acidosis, and hepatitis B exacerbations. Suitable for patients over three months and deemed safe in pregnancy, lamivudine is recognized as an essential medicine, underscoring its pivotal role in antiretroviral pharmacotherapy despite potential genotypic resistance mutations.\n\nDRUG 3 NAME: Metoprolol\nDRUG 3 BACKGROUND INFORMATION: Metoprolol, a cardioselective \u03b21-adrenergic receptor antagonist, is clinically utilized in the management of angina pectoris, hypertension, tachyarrhythmias, post-myocardial infarction secondary prophylaxis, and migraine prophylaxis. Its therapeutic efficacy is mediated via negative chronotropic and inotropic effects which result in decreased myocardial oxygen demand and improved exercise tolerance. The pharmacokinetics of metoprolol is influenced by hepatic cytochrome P450 2D6 isoenzyme variability leading to significant interpatient variability in drug metabolism, necessitating individualized dosing. Adverse effects prominently include insomnia, asthenia, presyncope, and gastrointestinal disturbances, with higher doses presenting risk for pronounced toxicity. Though teratogenic risk during pregnancy has not been conclusively excluded, its excretion into breast milk is considered clinically insignificant. Metoprolol is widely dispensed, reflecting its inclusion in the WHO's Essential Medicines, and its prescription frequency underscores its pivotal role in cardiovascular therapeutics.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Candesartan-cholecystitis-Lamivudine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamivudine-dysarthria-Metoprolol\n"}]}}
{"custom_id": "Fenofibrate-Modafinil-Bimatoprost-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fenofibrate\nDRUG 1 BACKGROUND INFORMATION: Fenofibrate, a lipid-modifying agent of the fibrate class, functions primarily through agonism of the peroxisome proliferator-activated receptor alpha (PPAR\u03b1), effectuating enhanced oxidation of fatty acids, increased lipoprotein lipase synthesis, and reduced hepatic production of apolipoprotein C-III, thereby leading to a reduction in triglyceride levels and modification of low-density lipoprotein (LDL) particle size. Its therapeutic efficacy, particularly in dyslipidemic profiles characterized by hypertriglyceridemia and low HDL cholesterol, albeit less statistically robust compared to HMG-CoA reductase inhibitors (statins), offers cardioprotective benefits within select demographic cohorts predisposed to atherogenic dyslipidemia. Gastrointestinal disturbances, hepatotoxicity, myopathy, and hypersensitivity reactions such as toxic epidermal necrolysis can manifest as dose-related adverse effects, while contraindications include pregnancy and lactation due to teratogenic potential. Despite its availability as a cost-effective generic, fenofibrate's clinical application necessitates concurrent dietary management to maximize therapeutic outcomes and mitigate risks of severe adverse sequelae like rhabdomyolysis, pancreatitis, and cholelithiasis.\n\nDRUG 2 NAME: Modafinil\nDRUG 2 BACKGROUND INFORMATION: Modafinil, chemically a CNS stimulant and eugeroic agent, is principally administered for narcolepsy but extends its indication to obstructive sleep apnea and shift work sleep disorder to augment wakefulness through oral administration. Although it is pharmacologically effective at ameliorating excessive somnolence, the drug's safety profile denotes common adverse effects such as anxiety, insomnia, dizziness, and cephalalgia, with potential for severe hypersensitivity reactions and psychiatric sequelae. Given its restricted clearance for populations under 17 by the FDA, usage mandates caution, notably in teratogenic contexts, as prenatal exposure may provoke fetal harm. Its application as a nootropic for cognitive augmentation in non-sleep deprived cohorts presents ambiguous outcomes, with literature delineating mixed efficacy on attention and executive function metrics, thereby juxtaposing potential off-label abuse against dubious therapeutic gains.\n\nDRUG 3 NAME: Bimatoprost\nDRUG 3 BACKGROUND INFORMATION: Bimatoprost, sold under the brand name Lumigan among others, is a medication used to treat high pressure inside the eye including glaucoma. Specifically it is used for open angle glaucoma when other agents are not sufficient. It may also be used to increase the size of the eyelashes. It is used as an eye drop and effects generally occur within four hours.\nCommon side effects include red eyes, dry eyes, change in color of the eyes, blurry vision, and cataracts. Use during pregnancy or breastfeeding is generally not recommended. It is a prostaglandin analog and works by increasing the outflow of aqueous fluid from the eyes.\nBimatoprost was approved for medical use in the United States in 2001. It is available as a generic medication. In 2022, it was the 195th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Fenofibrate-gastric inflammation-Modafinil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Modafinil-nocturia-Bimatoprost\n"}]}}
{"custom_id": "Naproxen-Lamotrigine-Salmeterol-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Naproxen\nDRUG 1 BACKGROUND INFORMATION: Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), exerts its pharmacological effects by non-selectively inhibiting cyclooxygenase (COX) enzymes, thereby attenuating the synthesis of pro-inflammatory prostaglandins, which are pivotal in the pathophysiology of pain, menstrual dysmenorrhea, and inflammatory diseases such as rheumatoid arthritis and gout. Administered orally in both immediate and delayed-release formulations, naproxen reaches therapeutic plasma concentrations within one hour, with a duration of action extending up to twelve hours, facilitating its utility in both acute and chronic settings. The sodium salt variant enhances oral solubility and absorption kinetics. While commonly associated with adverse effects including gastrointestinal discomfort, dizziness, and hypersensitivity reactions, more severe risks include cardiovascular thrombotic events and gastrointestinal bleeding, albeit with potentially a lower myocardial infarction risk relative to other NSAIDs. Its use is contraindicated in the presence of renal impairment and during the third trimester of pregnancy. Metabolic clearance occurs hepatically via biotransformation to inactive metabolites, with excretion primarily renal. Naproxen's widespread prescription, evident from over 7 million prescriptions in 2022 in the U.S., underscores its established therapeutic role, despite the potential for adverse event profiles.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Salmeterol\nDRUG 3 BACKGROUND INFORMATION: Salmeterol is a long-acting \u03b22 adrenergic receptor agonist (LABA) used in the treatment and prevention of asthma symptoms and control of chronic obstructive pulmonary disease (COPD) symptoms. Symptoms of bronchospasm include shortness of breath, wheezing, coughing and chest tightness. It is also used to prevent breathing difficulties during exercise (exercise-induced bronchoconstriction).\nIt was patented in 1983 and came into medical use in 1990. It is marketed as Serevent in the US. It is available as a dry-powder inhaler (DPI) that releases a powdered form of the drug. It was previously available as a metered-dose inhaler (MDI) but was discontinued in the US in 2002. It is available as an MDI in other countries as of 2020.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Naproxen-abnormal EEG-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-erythema-Salmeterol\n"}]}}
{"custom_id": "Citalopram-Gemfibrozil-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Citalopram\nDRUG 1 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 2 NAME: Gemfibrozil\nDRUG 2 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Sildenafil\nDRUG 3 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Citalopram-metabolic encephalopathy-Gemfibrozil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Gemfibrozil-erythema-Sildenafil\n"}]}}
{"custom_id": "Cimetidine-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-erythema-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "Fentanyl-Ketorolac-Oxaprozin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Fentanyl\nDRUG 1 BACKGROUND INFORMATION: Fentanyl, a synthetic piperidine opioid agonist, demonstrates exceptional analgesic efficacy, with \u03bc-opioid receptor affinity rendering it 50-100 times more potent than morphine. Clinically, it is indispensable for managing severe pain in oncologic contexts and post-operative recovery, administered under brand names such as Actiq, Duragesic, and Sublimaze. The pharmacokinetic profile facilitates rapid onset across administration routes, thus posing significant overdose risk even at minimal doses. Adverse pharmacodynamics encompass addiction potential, central nervous system depression leading to respiratory compromise, and a range of neuropsychiatric disturbances, including narcotic delirium and hypotensive coma, exacerbated synergistically by concurrent alcohol or co-ingestants like cocaine and heroin. Although opioid antagonists such as naloxone are efficacious in overdose scenarios, fentanyl\u2019s high receptor occupancy and potency often necessitate multiple reversal attempts. Epidemiologically, fentanyl supersedes other synthetic opioids, catalyzing an overdose epidemic exacerbated by clandestine synthesis and poly-drug formulations, complicating therapeutic interventions and forensic investigations. Proactive measures, including test kits and advanced analytical protocols, are critical in mitigating rampant illicit distribution, underpinned by fentanyl\u2019s streamlined synthesis and distribution adaptability.\n\nDRUG 2 NAME: Ketorolac\nDRUG 2 BACKGROUND INFORMATION: Ketorolac, marketed under names such as Toradol, Acular, and Sprix, is a potent nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of moderate to severe nociceptive pain with a treatment limitation not exceeding six to seven days, varying by country guidelines. Administration routes include oral, nasal, intravenous, intramuscular, and ophthalmic, with onset of analgesia within one hour and duration of efficacy up to eight hours. Its mechanism of action involves the inhibition of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), resulting in the attenuation of prostaglandin synthesis, and it possesses ancillary antipyretic properties. Common adverse reactions encompass sedation, vertigo, gastrointestinal discomfort, and emesis, while severe complications may involve gastrointestinal hemorrhage, nephrotoxicity, myocardial infarction, bronchospasm, heart failure, and hypersensitivity reactions. It is contraindicated in later stages of gestation and lactation due to potential fetal and neonatal risks. Despite its initial appeal as a non-opioid analgesic alternative with lower addictive potential, its correlation with significant adverse outcomes such as gastrointestinal and renal sequelae led to market withdrawal in specific regions like Germany. As a robust prostaglandin synthesis inhibitor, ketorolac compromises renal autoregulation under conditions of hemodynamic stress or elevated catecholamine states, limiting its utilization in those with underlying renal or cardiovascular vulnerabilities.\n\nDRUG 3 NAME: Oxaprozin\nDRUG 3 BACKGROUND INFORMATION: Oxaprozin, also known as oxaprozinum, is a nonsteroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. Chemically, it is a propionic acid derivative. Safety and efficacy has been established in children over 6 years with juvenile rheumatoid arthritis only, and there is an increased risk of adverse reactions in the elderly population.\nIt was patented in 1967 and approved for medical use in 1983.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Fentanyl-Adenopathy-Ketorolac\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ketorolac-gastric inflammation-Oxaprozin\n"}]}}
{"custom_id": "Alfuzosin-Benazepril-Terazosin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alfuzosin\nDRUG 1 BACKGROUND INFORMATION: Alfuzosin, sold under the brand name Uroxatral among others, is a medication of the \u03b11 blocker class. It is used to treat benign prostatic hyperplasia (BPH).\nAs an antagonist of the \u03b11-adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making urination easier. \nAlfuzosin was patented in 1978 and approved for medical use in 1988. It was approved in the US for benign prostatic hyperplasia in 2003. In 2020, it was the 336th-most commonly prescribed medication in the United States, with more than 700 thousand prescriptions.\n\nDRUG 2 NAME: Benazepril\nDRUG 2 BACKGROUND INFORMATION: Benazepril, an ACE inhibitor marketed as Lotensin, is administered orally for the management of hypertension, heart failure, and diabetic nephropathy by attenuating the renin-angiotensin-aldosterone system activity. Formulations include benazepril/hydrochlorothiazide and benazepril/amlodipine combinations, targeting synergistic pathways for antihypertensive efficacy. The pharmacodynamic profile includes adverse reactions such as asthenia, orthostatic dizziness, and cough, while severe adverse events consist of potential nephrotoxicity, hypotension, hyperkalemia, and angioedema. Teratogenic risks disallow its use during gestation, contrasting with permissible lactational use. Its pharmacokinetic properties have secured its status as a widely prescribed, generic therapeutic, illustrated by over three million prescriptions in the U.S. in 2022.\n\nDRUG 3 NAME: Terazosin\nDRUG 3 BACKGROUND INFORMATION: Terazosin, sold under the brand name Hytrin among others, is a medication used to treat symptoms of an enlarged prostate and high blood pressure. For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, headache, feeling tired, swelling, nausea, and low blood pressure with standing. Severe side effects may include priapism and low blood pressure. Prostate cancer should be ruled out before starting treatment. It is an alpha-1 blocker and works by relaxing blood vessels and the opening of the bladder.\nTerazosin was patented in 1975 and came into medical use in 1985. It is available as a generic medication. In 2021, it was the 234th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alfuzosin-Decreased Libido-Benazepril\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Benazepril-apoplexy-Terazosin\n"}]}}
{"custom_id": "Candesartan-mitomycin C-vincristine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Candesartan\nDRUG 1 BACKGROUND INFORMATION: Candesartan is an angiotensin receptor blocker used mainly for the treatment of high blood pressure and congestive heart failure. Candesartan has a very low maintenance dose. Like olmesartan, the metabolism of the drug is unusual as it is a cascading prodrug. Candesartan has good bioavailibility and is the most potent by weight of the AT-1 receptor antagonists.\nIt was patented in 1990 and approved for medical use in 1997.\n\nDRUG 2 NAME: mitomycin C\nDRUG 2 BACKGROUND INFORMATION: Mitomycin C is a mitomycin that is used as a  chemotherapeutic agent by virtue of its antitumour activity.\n\nDRUG 3 NAME: vincristine\nDRUG 3 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Candesartan-arterial pressure NOS increased-mitomycin C\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): mitomycin C-myelodysplasia-vincristine\n"}]}}
{"custom_id": "Cimetidine-Citalopram-oxybutynin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Citalopram\nDRUG 2 BACKGROUND INFORMATION: Citalopram, a chiral bicyclic phthalane derivative and selective serotonin reuptake inhibitor (SSRI), is primarily employed in the pharmacotherapy of major depressive disorder, obsessive-compulsive disorder, panic disorder, and social phobia through modulation of serotonergic neurotransmission. The therapeutic latency ranges from one to four weeks post-administration. It is predominantly administered orally, though parenteral administration via intravenous injection is utilized in specific regions to expedite therapeutic onset. The pharmacokinetic profile of citalopram encompasses hepatic metabolism predominantly via CYP2C19, CYP3A4, and CYP2D6, yielding demethylated metabolites. It is imperative to monitor for adverse reactions, including, but not limited to, gastrointestinal disturbances, insomnia, sexual dysfunction, tremors, somnolence, hyperhidrosis, serotonin toxicity, and cardiotoxicity as manifested by QT interval prolongation. Contraindications entail concurrent MAO inhibitor therapy due to risk of serotonin syndrome and potential teratogenicity warrants cautious use in pregnancy. The potential for exacerbating suicidality in individuals under 25 necessitates vigilant monitoring. Citalopram's clinical prominence is evidenced by its inclusion in the WHO's List of Essential Medicines and its extensive prescribing frequency in the United States, underscoring its integral role in psychiatric treatment regimens.\n\nDRUG 3 NAME: oxybutynin\nDRUG 3 BACKGROUND INFORMATION: Oxybutynin, marketed as Ditropan, is a quintessential anticholinergic agent employed predominantly for the amelioration of overactive bladder symptoms, capitalizing on its potent antimuscarinic properties that effectively circumvent acetylcholine-mediated smooth muscle contractions. Its pharmacotherapeutic action, analogous to tolterodine, darifenacin, and solifenacin, renders it a superior first-line therapeutic option due to its robust safety and efficacy profile over prolonged usage, despite plausible off-label utilizations in hyperhidrosis management. Contrarily, its application for pediatric nocturnal enuresis has seen diminished prevalence, given its questionable efficacy. Administrable orally or transdermally, oxybutynin's pharmacokinetic profile necessitates vigilance regarding adverse effects such as xerostomia, gastrointestinal hypomotility, and thermoregulatory dysfunction, encompassing severe sequelae like urinary retention and thermophilic impairments manifesting as heat stroke. Its teratogenic and lactogenic safety paradigms remain speculative, underscoring the need for judicious administration during pregnancy and lactation. As a generically available pharmacologic entity, it maintains substantial prescription frequency, embodying a pivotal role in managing cholinergic-mediated urological disorders.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-gastric inflammation-Citalopram\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Citalopram-cholecystitis-oxybutynin\n"}]}}
{"custom_id": "Famotidine-Sildenafil-Acamprosate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 3 NAME: Acamprosate\nDRUG 3 BACKGROUND INFORMATION: Acamprosate, sold under the brand name Campral, is a medication which reduces cravings in alcoholism. It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals, as it only addresses withdrawal symptoms and not psychological dependence. It facilitates a reduction in alcohol consumption as well as full abstinence when used in combination with psychosocial support or other drugs that address the addictive behavior.\nSerious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side effect. It is unclear if use is safe during pregnancy.\nIt is on the World Health Organization's List of Essential Medicines.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-gastric inflammation-Sildenafil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sildenafil-loss of weight-Acamprosate\n"}]}}
{"custom_id": "Alprazolam-Lidocaine-Pamidronic acid-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Alprazolam\nDRUG 1 BACKGROUND INFORMATION: Alprazolam is a high-affinity triazolobenzodiazepine functioning as a potent anxiolytic agent through modulation of the GABA_A receptor chloride channel activity, facilitating enhanced inhibitory neurotransmission. Its pharmacodynamic profile encompasses rapid onset and moderate duration of action, predominantly prescribed for anxiety spectrum disorders, including panic disorder and GAD, and adjunctively for chemotherapy-related emesis control. The pharmacokinetic trajectory involves oral administration, exhibiting bioavailability conducive to therapeutic efficacy within a week for GAD. The acute adverse neurological sequelae are characterized by CNS depression manifesting as somnolence, psychomotor impairment, cognitive attenuation, and dose-dependent anterograde amnesia. Tolerance development mitigates some sedative effects over time. Abrupt cessation precipitates benzodiazepine withdrawal symptomatology. As a Schedule IV controlled substance, alprazolam's potential for abuse and dependency necessitates judicious prescription monitoring. Its clinical ubiquity is substantiated by its standing as the 41st most prescribed drug in the US, with significant generic dissemination.\n\nDRUG 2 NAME: Lidocaine\nDRUG 2 BACKGROUND INFORMATION: Lidocaine, or lignocaine, is a quintessential amino amide local anesthetic utilized extensively for its neuromodulatory and cardiac electrophysiological properties. As a class Ib antiarrhythmic agent, lidocaine exerts its mechanistic effect via blockade of voltage-gated sodium channels, thereby attenuating myocardial depolarization and stabilizing aberrant conduction pathways responsible for ventricular tachycardia and fibrillation. Its onset of action, contingent upon peripheral nerve administration, is typically rapid, achieving effective anesthesia within minutes, with a duration ranging from 30 minutes to three hours, and efficacy can be potentiated when co-administered with adrenaline due to vasoconstriction and augmented tissue retention. Topical formulations enhance transdermal absorption for sensory blockade across dermal and mucosal surfaces. In systemic circulation, particularly when administered intravenously, lidocaine may induce neurotoxic side effects including CNS agitation, visual disturbances, paresthesia, and emesis, in addition to cardiovascular effects such as hypotension and dysrhythmogenesis. Caution is advised with intra-articular administration due to chondrotoxicity concerns, and dose adjustments are necessary in hepatic insufficiency, yet it remains a favorable option in patients with hypersensitivity to ester-type anesthetics like tetracaine. Due to its obstetric safety profile, lidocaine is deemed viable during gestation and its inclusion in the WHO's List of Essential Medicines underlines its critical therapeutic value and accessibility as a generic formulation.\n\nDRUG 3 NAME: Pamidronic acid\nDRUG 3 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Alprazolam-right heart failure-Lidocaine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lidocaine-trigeminal neuralgia-Pamidronic acid\n"}]}}
{"custom_id": "Furosemide-vincristine-Torasemide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: vincristine\nDRUG 2 BACKGROUND INFORMATION: Vincristine, a vinca alkaloid derived from Catharanthus roseus, acts as a mitotic inhibitor by binding to tubulin, thus disrupting microtubule assembly and arresting metaphase progression in neoplastic cells. Clinically administered intravenously, it exhibits therapeutic efficacy against malignancies such as acute lymphoblastic leukemia, acute myeloid leukemia, Hodgkin's lymphoma, neuroblastoma, and small cell lung carcinoma. Its pharmacological profile is marked by both neuropathic and systemic side effects, including peripheral neuropathy, alopecia, gastrointestinal stasis, and neuromuscular impairments, alongside potential for severe toxicities like myelosuppression and pulmonary compromise. Teratogenic risks contraindicate its use in gravid patients. Owing to its profound neurotoxicity, inadvertent intrathecal administration can precipitate fatal outcomes, underscoring the critical importance of adhering to strict administration protocols. Recognized for its oncologic utility, vincristine remains a cornerstone agent within chemotherapeutic regimens and is listed on the WHO's Essential Medicines index.\n\nDRUG 3 NAME: Torasemide\nDRUG 3 BACKGROUND INFORMATION: Torasemide, also known as torsemide, is a diuretic medication used to treat fluid overload due to heart failure, kidney disease, and liver disease. It is a less preferred treatment for high blood pressure. It is taken by mouth or by injection into a vein.\nCommon side effects include headache, increased urination, diarrhea, cough, and dizziness. Other side effects may include hearing loss and low blood potassium. Torasemide is a sulfonamide and loop diuretic. Use is not recommended in pregnancy or breastfeeding. It works by decreasing the reabsorption of sodium by the kidneys.\nTorasemide was patented in 1974 and came into medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2022, it was the 184th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Furosemide-amyloidosis-vincristine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): vincristine-drug toxicity NOS-Torasemide\n"}]}}
{"custom_id": "Metronidazole-Repaglinide-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Metronidazole\nDRUG 1 BACKGROUND INFORMATION: Metronidazole, a nitroimidazole antimicrobial agent, exerts its therapeutic efficacy through the reductive activation of its nitro group under anaerobic conditions, leading to the generation of radical intermediates that disrupt nucleic acid synthesis and result in microbial cell death. This antimicrobial exhibits a broad spectrum of antiprotozoal and antibacterial activity, making it efficacious in treating a variety of conditions, including pelvic inflammatory disease, bacterial vaginosis, and anaerobic infections such as Clostridioides difficile colitis, particularly when first-line options like vancomycin are unavailable. Pharmacodynamically, metronidazole can be administered via oral, topical, or intravenous routes, allowing flexibility in clinical application. However, its use is occasionally accompanied by adverse reactions such as gastrointestinal disturbances, neurotoxicity including seizures, and hypersensitivity responses, necessitating cautious application, particularly in pregnant populations where teratogenic potential is debated, though generally compatible with lactation. Despite these considerations, metronidazole remains a cornerstone in antimicrobial treatment paradigms, reflected by its inclusion in the WHO's List of Essential Medicines and high prescription rates globally.\n\nDRUG 2 NAME: Repaglinide\nDRUG 2 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Metronidazole-erythema-Repaglinide\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Repaglinide-nasal sinus congestion-Perindopril\n"}]}}
{"custom_id": "Furosemide-Lamotrigine-Fosphenytoin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Furosemide\nDRUG 1 BACKGROUND INFORMATION: Furosemide, a potent loop diuretic, exerts its pharmacological action by inhibiting the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, thus profoundly augmenting natriuresis and diuresis, which alleviates conditions of edema secondary to cardiac, hepatic, or renal insufficiencies. Additionally utilized in the management of hypertension, furosemide yields rapid onset of action with intravenous administration effectuating within five minutes, whereas oral ingestion manifests systemic absorption and efficacy within an hour. Adverse effects encompass orthostatic hypotension, tinnitus, and photosensitivity, with severe risks including electrolyte imbalances such as hypokalemia, along with potential nephrotoxicity and ototoxicity. Clinicians are advised to diligently monitor serum electrolytes (notably potassium), bicarbonate, renal indices (creatinine, BUN), and hepatic function parameters. Despite its inclusion on the World Health Organization's List of Essential Medicines, furosemide's utility is tempered by its status on the World Anti-Doping Agency's list of prohibited substances, attributed to its potential misuse for concealing illicit performance-enhancing drug usage, alongside its veterinary application for managing exercise-induced pulmonary hemorrhage in equines.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Fosphenytoin\nDRUG 3 BACKGROUND INFORMATION: Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.\nFosphenytoin was developed in 1996.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Furosemide-weight gain-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-bradycardia-Fosphenytoin\n"}]}}
{"custom_id": "Doxazosin-Pamidronic acid-thiotepa-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Doxazosin\nDRUG 1 BACKGROUND INFORMATION: Doxazosin, sold under the brand name Cardura among others, is a medication used to treat symptoms of benign prostatic hyperplasia (enlarged prostate), hypertension (high blood pressure), and post-traumatic stress disorder (PTSD). For high blood pressure, it is a less preferred option. It is taken by mouth.\nCommon side effects include dizziness, sleepiness, swelling, nausea, shortness of breath, and abdominal pain. Severe side effects may include low blood pressure with standing, an irregular heart beat, and priapism. It is a selective \u03b11-adrenergic blocker in the quinazoline class of compounds.\nDoxazosin was patented in 1977 and came into medical use in 1988. It is available as a generic medication. In 2022, it was the 180th most commonly prescribed medication in the United States, with more than 2 million prescriptions.\n\nDRUG 2 NAME: Pamidronic acid\nDRUG 2 BACKGROUND INFORMATION: Pamidronic acid or pamidronate disodium or APD (marketed as Aredia among others), is a nitrogen-containing bisphosphonate used to prevent osteoporosis.\nIt was patented in 1971 and approved for medical use in 1987.\n\nDRUG 3 NAME: thiotepa\nDRUG 3 BACKGROUND INFORMATION: Thiotepa (N,N',N''(-triethylenethiophosphoramide, INN), sold under the brand name Tepadina among others, is an anti-cancer medication.\nThiotepa is an organophosphorus compound with the formula (C2H4N)3PS.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Doxazosin-atelectasis-Pamidronic acid\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Pamidronic acid-erythema-thiotepa\n"}]}}
{"custom_id": "Celecoxib-Desloratadine-solifenacin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Celecoxib\nDRUG 1 BACKGROUND INFORMATION: Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, functions as a nonsteroidal anti-inflammatory drug (NSAID) utilized primarily for its analgesic and anti-inflammatory efficacy in osteoarthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dysmenorrhea, acute pain management, and juvenile rheumatoid arthritis. Additionally, celecoxib has prophylactic applications in reducing colorectal adenomatous formations in familial adenomatous polyposis due to its COX-2 inhibition, which mitigates pro-inflammatory prostaglandin synthesis while sparing COX-1, ostensibly minimizing gastrointestinal mucosal damage relative to non-selective NSAIDs. The pharmacokinetics permit oral administration, with pharmacodynamic effects commencing typically within one hour post-ingestion. Notable adverse reactions span gastrointestinal disturbances such as abdominal pain, nausea, and diarrhea, with severe risk profiles including cardiovascular thrombotic events, gastrointestinal perforation, renal impairment, and hypersensitivity reactions like anaphylaxis, contraindicating its use in populations with significant cardiovascular risk profiles. The risk profile parallels that of other NSAIDs like ibuprofen and naproxen, and caution is advised during late-stage gestation and lactation. Celecoxib's generic availability and widespread prescription underscore its clinical significance, albeit with requisite consideration of its potential side-effect burden.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 3 NAME: solifenacin\nDRUG 3 BACKGROUND INFORMATION: Solifenacin, sold as the brand name Vesicare among others, is a medicine used to treat overactive bladder and neurogenic detrusor overactivity (NDO). It may help with incontinence, urinary frequency, and urinary urgency. \nBenefits appear similar to other medications in the class. It is taken by mouth.\nCommon side effects include dry mouth, constipation, and urinary tract infection. Severe side effects may include urinary retention, QT prolongation, hallucinations, glaucoma, and anaphylaxis. It is unclear if use is safe during pregnancy. It is of the antimuscarinic class and works by decreasing bladder contractions.\nSolifenacin was approved for medical use in the United States in 2004. In 2022, it was the 210th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Celecoxib-cholecystitis-Desloratadine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Desloratadine-bursitis-solifenacin\n"}]}}
{"custom_id": "Haloperidol-indometacin-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Haloperidol\nDRUG 1 BACKGROUND INFORMATION: Haloperidol, a butyrophenone derivative, exerts its therapeutic efficacy as a typical antipsychotic primarily through potent antagonism of central dopaminergic D2 receptors, ameliorating positive psychotic symptoms in conditions such as schizophrenia, Tourette syndrome, acute mania in bipolar disorder, delirium, and alcohol withdrawal-related hallucinations. Exhibiting rapid onset post-oral or parenteral administration, haloperidol can be deployed via bi-weekly intramuscular depot injections for long-term management of schizophrenia spectrum disorders in non-compliant patients. While efficacious, haloperidol is implicated in extrapyramidal side effects, notably irreversible tardive dyskinesia and akathisia, along with the rare but severe neuroleptic malignant syndrome and dose-dependent QT interval prolongation, the latter significantly observed with intravenous routes. Its contraindication in patients with Parkinson's disease and increased mortality risk in dementia-related psychosis underscore the necessity for judicious application. Adverse fetal outcomes restrict its use during pregnancy. Despite these safety concerns, haloperidol maintains its status as an essential medication per the World Health Organization's compendium, continually ranking among the most prescribed antipsychotics in clinical practice.\n\nDRUG 2 NAME: indometacin\nDRUG 2 BACKGROUND INFORMATION: Indometacin, also known as indomethacin, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used as a prescription medication to reduce fever, pain, stiffness, and swelling from inflammation. It works by inhibiting the production of prostaglandins, endogenous signaling molecules known to cause these symptoms. It does this by inhibiting cyclooxygenase, an enzyme that catalyzes the production of prostaglandins.\nIt was patented in 1961 and approved for medical use in 1963. It is on the World Health Organization's List of Essential Medicines. In 2022, it was the 256th most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 3 NAME: Sildenafil\nDRUG 3 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Haloperidol-erythema multiforme-indometacin\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): indometacin-apoplexy-Sildenafil\n"}]}}
{"custom_id": "acetazolamide-Lamotrigine-Metolazone-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: acetazolamide\nDRUG 1 BACKGROUND INFORMATION: Acetazolamide, marketed under the trade name Diamox, serves as a versatile pharmaceutical agent within the realm of carbonic anhydrase inhibitors, effectively modulating intraocular pressure via the diminution of aqueous humor production and osmolality. Its clinical utility spans across conditions such as glaucoma\u2014both open-angle and acute angle closure\u2014epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, and heart failure, with an ancillary role in urinary alkalinization. Therapeutic administration is achievable through oral and intravenous modalities. Mechanistically, acetazolamide exerts its effects by disrupting the equilibria of carbon dioxide hydration and subsequent bicarbonate ion production, thereby reducing intracellular hydrogen ion availability. The pharmacodynamic profile encompasses neuro-sensory side effects like paresthesia and tinnitus, alongside anorexia, emesis, and somnolence. Contraindications are notable in individuals with renal or hepatic impairment, and those with hypersensitivity to sulfonamide derivatives. As a diuretic and enzymatic inhibitor, it holds a position on the WHO's List of Essential Medicines, emphasizing its critical global accessibility as a generic formulation.\n\nDRUG 2 NAME: Lamotrigine\nDRUG 2 BACKGROUND INFORMATION: Lamotrigine, a phenyltriazine anticonvulsant, is primarily utilized in the pharmacological management of epilepsy, encompassing focal, tonic-clonic, and Lennox-Gastaut syndrome seizures, as well as serving as a mood-stabilizing agent in bipolar disorder. While it does not consistently ameliorate acute depressive states in bipolar disorders outside of severe depression contexts, it efficaciously mitigates the risk of recurrent depressive episodes in euthymic individuals. Additionally, lamotrigine is prescribed off-label for major depressive disorder and depersonalization-derealization disorder. Its pharmacodynamics are hypothesized to involve the inhibition of excitatory neurotransmitter release through modulation of voltage-sensitive sodium channels and voltage-gated calcium channels. Despite its therapeutic efficacy, lamotrigine's adverse effect profile includes both common side effects such as nausea, somnolence, headache, emesis, ataxia, and dermatological reactions, and serious reactions like hemolytic anemia, suicidality, and potentially fatal Stevens\u2013Johnson syndrome.\n\nDRUG 3 NAME: Metolazone\nDRUG 3 BACKGROUND INFORMATION: Metolazone is a thiazide-like diuretic marketed under the brand names Zytanix, Metoz, Zaroxolyn, and Mykrox. It is primarily used to treat congestive heart failure and high blood pressure. Metolazone indirectly decreases the amount of water reabsorbed into the bloodstream by the kidney, so that blood volume decreases and urine volume increases. This lowers blood pressure and prevents excess fluid accumulation in heart failure. Metolazone is sometimes used together with loop diuretics such as furosemide or bumetanide, but these highly effective combinations can lead to dehydration and electrolyte abnormalities.\nIt was patented in 1966 and approved for medical use in 1974.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): acetazolamide-hiccough-Lamotrigine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Lamotrigine-still birth-Metolazone\n"}]}}
{"custom_id": "Ibuprofen-Repaglinide-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ibuprofen\nDRUG 1 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 2 NAME: Repaglinide\nDRUG 2 BACKGROUND INFORMATION: Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from \u03b2-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere.  In Japan it is produced by Dainippon Sumitomo Pharma.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-renal abscess-Repaglinide\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Repaglinide-nasal sinus congestion-Perindopril\n"}]}}
{"custom_id": "Gemfibrozil-Sildenafil-Acamprosate-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gemfibrozil\nDRUG 1 BACKGROUND INFORMATION: Gemfibrozil, sold under the brand name Lopid among others, is a medication used to treat abnormal blood lipid levels. It is generally less preferred than statins. Use is recommended together with dietary changes and exercise. It is unclear if it changes the risk of heart disease. It is taken by mouth.\nCommon side effects include headache, dizziness, feeling tired, and intestinal upset. Serious side effects may include angioedema, gallstones, liver problems, and muscle breakdown. Use in pregnancy and breastfeeding is of unclear safety. It belongs to the fibrates group of medications and works by decreasing the breakdown of lipids in fat cells.\nGemfibrozil was patented in 1968, and came into medical use in 1982. It is available as a generic medication. In 2022, it was the 231st most commonly prescribed medication in the United States, with more than 1 million prescriptions.\n\nDRUG 2 NAME: Sildenafil\nDRUG 2 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 3 NAME: Acamprosate\nDRUG 3 BACKGROUND INFORMATION: Acamprosate, sold under the brand name Campral, is a medication which reduces cravings in alcoholism. It is thought to stabilize chemical signaling in the brain that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for alcohol use disorder in most individuals, as it only addresses withdrawal symptoms and not psychological dependence. It facilitates a reduction in alcohol consumption as well as full abstinence when used in combination with psychosocial support or other drugs that address the addictive behavior.\nSerious side effects include allergic reactions, abnormal heart rhythms, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Diarrhea is the most common side effect. It is unclear if use is safe during pregnancy.\nIt is on the World Health Organization's List of Essential Medicines.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Gemfibrozil-erythema-Sildenafil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sildenafil-loss of weight-Acamprosate\n"}]}}
{"custom_id": "alendronic acid-Dipyridamole-Sildenafil-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: alendronic acid\nDRUG 1 BACKGROUND INFORMATION: Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.\nCommon side effects (1 to 10% of patients) include constipation, abdominal pain, nausea, and acid reflux. Use is not recommended during pregnancy or in those with poor kidney function. Alendronic acid works by decreasing the activity of cells that break down bone.\nAlendronic acid was first described in 1978 and approved for medical use in the United States in 1995. It is available as a generic medication. In 2022, it was the 103rd most commonly prescribed medication in the United States, with more than 6 million prescriptions.\n\nDRUG 2 NAME: Dipyridamole\nDRUG 2 BACKGROUND INFORMATION: Dipyridamole, sold under the brand name Persantine among others, is an antiplatelet drug of the nucleoside transport inhibitor and PDE3 inhibitor class that inhibits blood clot formation when given chronically and causes blood vessel dilation when given at high doses over a short time.\n\nDRUG 3 NAME: Sildenafil\nDRUG 3 BACKGROUND INFORMATION: Sildenafil functions primarily as a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for catabolizing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This pharmacological activity results in the potentiation of nitric oxide-mediated vasodilation, thus enhancing blood flow to the corpus cavernosum and mitigating pulmonary arterial hypertension (PAH) through pulmonary vasodilation. The drug's pharmacokinetics include a rapid onset of action, typically within 20 minutes post-oral administration, and a duration of approximately two hours. Its bioavailability can be achieved via oral, intravenous, or sublingual administration. Concomitant use with nitrates or nitric oxide donors can precipitate severe hypotension, contraindicating concomitant administration. Side effects are often attributable to excessive peripheral vasodilation and can include headache, dyspepsia, facial flushing, and rare, albeit severe, adverse events such as vision or auditory impairment and priapism. Precision in its administration is imperative for individuals with cardiovascular pathology due to potential exacerbation of underlying conditions. Although efficacious in ED and PAH, its utility in female sexual dysfunction remains inconclusive.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): alendronic acid-erythema-Dipyridamole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dipyridamole-weight gain-Sildenafil\n"}]}}
{"custom_id": "Gabapentin-Minoxidil-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Gabapentin\nDRUG 1 BACKGROUND INFORMATION: Gabapentin, a prototypical member of the gabapentinoid class, is extensively utilized in the management of neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, as well as partial epileptic seizures. Its mechanism of action predominantly involves high-affinity binding to the \u03b12\u03b4-1 subunit of voltage-gated calcium channels, encoded by the CACNA2D1 gene, thereby attenuating the synaptic release of glutamate and consequent hyperexcitability within central neuronal circuits. Although effective in approximately 30-40% of patients with neuropathic pain, the pharmacodynamic profile necessitates cautious administration, particularly in patients with renal impairment, due to its propensity to induce sedation, dizziness, potential for respiratory depression, and a heightened suicidality risk as classified by the FDA. Gabapentin's pharmacokinetic traits and adverse event profile require vigilant therapeutic monitoring to mitigate risks and optimize clinical outcomes. It continues to be a staple in therapeutic regimens, as evidenced by its status as one of the most prescribed medications in the United States, albeit historical controversies concerning its marketing strategies by the originating pharmaceutical entities.\n\nDRUG 2 NAME: Minoxidil\nDRUG 2 BACKGROUND INFORMATION: Minoxidil  is a medication used for the treatment of high blood pressure and pattern hair loss. It is an antihypertensive and a vasodilator. It is available as a generic medication by prescription in oral tablet form and over-the-counter as a topical liquid or foam.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Gabapentin-insulin dependent diabetes mellitus-Minoxidil\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Minoxidil-thrombocytopenia-Perindopril\n"}]}}
{"custom_id": "Famotidine-Ticlopidine-Tirofiban-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Famotidine\nDRUG 1 BACKGROUND INFORMATION: Famotidine, sold under the brand name Pepcid among others, is a histamine H2 receptor antagonist medication that decreases stomach acid production. It is used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger\u2013Ellison syndrome. It is taken by mouth or by injection into a vein. It begins working within an hour.\nCommon side effects include headache, abdominal pain, diarrhea or constipation, and dizziness. Serious side effects may include pneumonia and seizures. Use in pregnancy appears safe but has not been well studied, while use during breastfeeding is not recommended.\nFamotidine was patented in 1979 and came into medical use in 1985. It is available as a generic medication. In 2022, it was the 49th most commonly prescribed medication in the United States, with more than 13 million prescriptions.\n\nDRUG 2 NAME: Ticlopidine\nDRUG 2 BACKGROUND INFORMATION: Ticlopidine, sold under the brand name Ticlid, is a medication used to reduce the risk of thrombotic strokes. It is an antiplatelet drug in the thienopyridine family which is an adenosine diphosphate (ADP) receptor inhibitor. Research initially showed that it was useful for preventing strokes and coronary stent occlusions. However, because of its rare but serious side effects of neutropenia and thrombotic microangiopathy it was primarily used in patients in whom aspirin was not tolerated, or in whom dual antiplatelet therapy was desirable. With the advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited.\nIt was patented in 1973 and approved for medical use in 1978.\n\nDRUG 3 NAME: Tirofiban\nDRUG 3 BACKGROUND INFORMATION: Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.\nIt is available as a generic medication.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Famotidine-Extrasystoles Ventricular-Ticlopidine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ticlopidine-thrombocytopenia-Tirofiban\n"}]}}
{"custom_id": "Cimetidine-Sumatriptan-Balsalazide-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Cimetidine\nDRUG 1 BACKGROUND INFORMATION: Cimetidine, sold under the brand name Tagamet among others, is a histamine H2 receptor antagonist that inhibits stomach acid production. It is mainly used in the treatment of heartburn and peptic ulcers.\nWith the development of proton pump inhibitors, such as omeprazole, approved for the same indications, cimetidine is available as an over-the-counter formulation to prevent heartburn or acid indigestion, along with the other H2-receptor antagonists.\nCimetidine was developed in 1971 and came into commercial use in 1977. Cimetidine was approved in the United Kingdom in 1976, and was approved in the United States by the Food and Drug Administration in 1979.\n\nDRUG 2 NAME: Sumatriptan\nDRUG 2 BACKGROUND INFORMATION: Sumatriptan, a triptan-class pharmacologic agent, serves as a selective agonist for serotonin 5-HT1B and 5-HT1D receptors, exerting its antimigraine efficacy via vasoconstrictive and neuronal inhibition pathways. Administrable via oral, nasal, or subcutaneous routes, sumatriptan yields therapeutic outcomes in migraine and cluster headache relief typically within a three-hour post-administration window. While the precise mechanistic underpinnings remain somewhat ambiguous, its receptor specificity precipitates adverse effects like chest pressure, fatigue, emesis, paraesthesia, and dizziness, with potential for inducing severe pathologies such as serotonin syndrome, myocardial infarction, cerebrovascular accidents, and convulsive events. Chronic or excessive application can instigate medication overuse headaches, and its safety profile remains inconclusive during gestation and lactation. Despite these considerations, its clinical utility is underscored by its inclusion on the World Health Organization's List of Essential Medicines, availability in generic forms, and its prescription prevalence. Sumatriptan exhibits ready incorporation into combination therapies, such as with naproxen, to enhance therapeutic efficacy.\n\nDRUG 3 NAME: Balsalazide\nDRUG 3 BACKGROUND INFORMATION: Balsalazide is an anti-inflammatory drug used in the treatment of inflammatory bowel disease. It is sold under the brand names Giazo, Colazal in the US and Colazide in the UK. It is also sold in generic form in the US by several generic manufacturers.\nIt is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis. It is in the category of disease-modifying antirheumatic drugs (DMARDs) family of medications. It is unclear exactly how it works.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Cimetidine-angiitis-Sumatriptan\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Sumatriptan-Difficulty breathing-Balsalazide\n"}]}}
{"custom_id": "Ziprasidone-Desloratadine-Telithromycin-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Ziprasidone\nDRUG 1 BACKGROUND INFORMATION: Ziprasidone, primarily marketed as Geodon, is a second-generation atypical antipsychotic exhibiting therapeutic efficacy in managing both schizophrenia and bipolar disorder, with formulary options for oral and intramuscular (IM) administration. The IM variant, ziprasidone mesylate trihydrate, is particularly leveraged for rapid amelioration of acute agitative states in schizophrenic patients, whereas oral administration utilizes the hydrochloride salt form. The pharmacodynamic profile of ziprasidone suggests a mechanism of action predicated on modulation of serotonergic (5-HT) and dopaminergic (D2) neurotransmitter pathways, although the precise mechanistic underpinnings remain elusive. The adverse effect spectrum spans neuromotor disturbances like tremors and tics, autonomic nervous system effects such as dry mouth and nausea, and characteristic psychotropic-induced sedation. Notably, ziprasidone presents a reduced risk of weight gain compared to its atypical counterparts. Despite its complex pharmacological profile, ziprasidone occupies a significant niche in psychopharmacotherapy, underscored by its prescription prevalence, ranking 282nd in the U.S. pharmaceutical landscape as of 2020 with over a million prescriptions circulated.\n\nDRUG 2 NAME: Desloratadine\nDRUG 2 BACKGROUND INFORMATION: Desloratadine sold under the brand name Aerius among others, is a tricyclic H1 inverse agonist that is used to treat allergies. It is an active metabolite of loratadine.\nIt was patented in 1984 and came into medical use in 2001. It was brought to the market in the US by Schering Corporation, later named Schering-Plough.\n\nDRUG 3 NAME: Telithromycin\nDRUG 3 BACKGROUND INFORMATION: Telithromycin is the first ketolide antibiotic to enter clinical use and is sold under the brand name of Ketek. It is used to treat community acquired pneumonia of mild to moderate severity. After significant safety concerns, the US Food and Drug Administration sharply curtailed the approved uses of the drug in early 2007.\nTelithromycin is a semi-synthetic erythromycin derivative. It is created by substituting a ketogroup for the cladinose sugar and adding a carbamate ring in the lactone ring. An alkyl-aryl moiety is attached to this carbamate ring. Furthermore, the oxygen at the 6 position is methylated, as is the case with clarithromycin, to achieve better acid-stability.\nIt was patented in 1994 and approved for medical use in 2001.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Ziprasidone-heart rate increased-Desloratadine\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Desloratadine-Sinus headache-Telithromycin\n"}]}}
{"custom_id": "Carvedilol-Ibuprofen-Midodrine-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Ibuprofen\nDRUG 2 BACKGROUND INFORMATION: Ibuprofen, a widely utilized nonsteroidal anti-inflammatory drug (NSAID), exerts its therapeutic effects primarily through the attenuation of cyclooxygenase (COX) enzymatic activity, thereby reducing the biosynthesis of pro-inflammatory prostaglandins. Indicated for alleviating nociceptive and inflammatory perturbations such as dysmenorrhea, migrainous episodes, and inflammatory arthropathies, ibuprofen demonstrates notable pharmacokinetics with onset of action within one hour post administration via oral or parenteral routes. Despite its efficacy, ibuprofen's pharmacodynamic profile correlates with several adverse outcomes, notably gastrointestinal mucosal irritation leading to potential bleeding, renal impairment with prolonged administration, and rare hepatotoxicity. It possesses a variable cardiovascular risk profile, posing increased myocardial infarction risk at higher dosages. Notably, ibuprofen is contraindicated in advanced gestational periods due to its deleterious fetal effects and can exacerbate asthmatic conditions. Although it constitutes a less potent anti-inflammatory than other NSAIDs, its inclusion in the WHO's List of Essential Medicines underscores its clinical utility across various domains. Despite its prevalence, ongoing vigilance is advised due to its side effect spectrum.\n\nDRUG 3 NAME: Midodrine\nDRUG 3 BACKGROUND INFORMATION: Midodrine, sold under the brand names ProAmatine and Orvaten among others, is an antihypotensive medication used to treat orthostatic hypotension (low blood pressure when standing) and urinary incontinence. It is taken by mouth.\nSide effects of midodrine include hypertension (high blood pressure), paresthesia, itching, goosebumps, chills, urinary urgency, urinary retention, and urinary frequency. Midodrine is a prodrug of its active metabolite desglymidodrine. This metabolite acts as a selective agonist of the \u03b11-adrenergic receptor. This in turn results in vasoconstriction and increased blood pressure.\nMidodrine was discovered by 1971 and was introduced for medical use in the United States in 1996.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-cholecystitis-Ibuprofen\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Ibuprofen-dry skin-Midodrine\n"}]}}
{"custom_id": "Carvedilol-Dexpramipexole-Trimethoprim-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: Carvedilol\nDRUG 1 BACKGROUND INFORMATION: Carvedilol, a nonselective beta-adrenergic blocker with alpha-1 adrenergic receptor antagonism, is clinically utilized for managing hypertension and chronic heart failure with reduced ejection fraction (HFrEF), often despite beta-blockers not being preferred first-line antihypertensives due to inferior cardiovascular outcomes and safety profiles relative to alternative hypertensives. While its pharmacodynamic mechanisms contributing to therapeutic efficacy in HFrEF remain incompletely elucidated, vasodilation resultant from alpha-1 blockade may play a role. Adverse reactions encompass orthostatic hypotension, asthenia, arthralgia, nausea, and dyspnea, with bronchospasm as a potential severe manifestation. The drug's pharmacokinetics necessitate cautious use during gestation and lactation and contraindicate administration in hepatic impairment cases. Despite exhibiting a broad safety spectrum, carvedilol's utilization extends to over 17 million annual prescriptions in the U.S., affirming its presence on the WHO's List of Essential Medicines and availability in generic formulations.\n\nDRUG 2 NAME: Dexpramipexole\nDRUG 2 BACKGROUND INFORMATION: Dexpramipexole is a first-in-class oral investigational medicine that lowers blood and tissue eosinophils before they can cause damage in the target organ. Dexpramipexole is being developed by Areteia Therapeutics and has the potential to be the first oral treatment ever approved for eosinophilic asthma. The eosinophil-targeting effects of oral dexpramipexole were discovered during its clinical development. Across five clinical trials, dexpramipexole has consistently been shown to significantly reduce blood eosinophil counts.\n\nDRUG 3 NAME: Trimethoprim\nDRUG 3 BACKGROUND INFORMATION: Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally (swallowed by mouth).\nCommon side effects include nausea, changes in taste, and rash. Rarely it may result in blood problems such as not enough platelets or white blood cells. Trimethoprim may cause sun sensitivity. There is evidence of potential harm during pregnancy in some animals but not humans. It works by blocking folate metabolism via dihydrofolate reductase in some bacteria, preventing creation of bacterial DNA and RNA and leading to bacterial cell death.\nTrimethoprim was first used in 1962. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): Carvedilol-gastric inflammation-Dexpramipexole\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dexpramipexole-weight gain-Trimethoprim\n"}]}}
{"custom_id": "phenytoin-Dapsone-Perindopril-DDI-Bio-1_hop", "method": "POST", "url": "/v1/chat/completions", "body": {"model": "gpt-4.1", "messages": [{"role": "developer", "content": "You are a helpful AI assistant who writes questions about DRUG-DRUG INTERACTIONS. You are given background information on three drugs and their interaction triples (in subject-predicate-object format), which describe the side effects or outcomes of taking two drugs together. \n\nTASK REQUIREMENTS:\n\n1. Write exactly one question integrating the background knowledge of each drug and its relationships. The answer must be Drug 3.\n2. The question may be as complex as desired, but it must be answerable.\n3. Do NOT mention the drugs by name in the question; use only their background descriptions.\n4. The question should **specifically test knowledge of the triple-described relationship or interaction, not just isolated facts about the provided drugs.**\n5. The answer should be only the name of the correct drug.\n6. Output in the following format:\n\nQuestion:\nAnswer:"}, {"role": "user", "content": "DRUG 1 NAME: phenytoin\nDRUG 1 BACKGROUND INFORMATION: Phenytoin (PHT), marketed as Dilantin, is a hydantoin derivative functioning as a voltage-gated sodium channel inhibitor, efficacious in mitigating hyperexcitable neuronal circuits characteristic of tonic-clonic and focal seizures, yet ineffective against absence seizures. Its prodrug, fosphenytoin, is formulated for intravenous administration to manage benzodiazepine-refractory status epilepticus. Pharmacokinetics reveal rapid onset within 30 minutes post-intravenous administration, with a therapeutic window extending approximately 24 hours; plasma concentration monitoring is imperative for dosage calibration. Adverse effects range from benign, such as gastrointestinal disturbances, to serious, including cerebellar degeneration, toxic epidermal necrolysis, and hematological suppression. Teratogenicity is documented, contraindicating its use in pregnancy, though lactation appears unaffected. Ethanol co-administration may perturb its antiepileptic efficacy. Despite the presence of a myriad of generic versions, phenytoin remains listed by WHO as essential due to its distinct pharmacodynamic profile and is widely prescribed, underscoring its significance in the therapeutic armamentarium for seizure disorders.\n\nDRUG 2 NAME: Dapsone\nDRUG 2 BACKGROUND INFORMATION: Dapsone, chemically delineated as 4,4'-sulfonyldianiline or diaminodiphenyl sulfone, operates as a bacteriostatic antimicrobial agent within the sulfone class, frequently co-administered with rifampicin and clofazimine in leprosy management. It serves as an adjunctive therapeutic in pneumocystis pneumonia prophylaxis and toxoplasmosis prevention within immunocompromised cohorts, as well as for dermatological conditions such as acne and dermatitis herpetiformis, available in both oral and topical formulations. Pharmacodynamically, dapsone's modes of action encompass inhibition of bacterial dihydropteroate synthetase, although it is associated with grave hematological adverse effects, notably hemolytic anemia exacerbated by glucose-6-phosphate dehydrogenase deficiency and agranulocytosis, alongside potential hepatotoxicity manifested as hepatic inflammation. Methemoglobinemia and dermatological hypersensitivity reactions, encompassing a variety of rash presentations, constitute additional risk factors. The teratogenic profile remains equivocal; however, continuation during gestation is advised in leprosy cases. Economically accessible as a generic formulation, dapsone retains its inclusion on the WHO Essential Medicines List, underscoring its clinical utility and indispensable status in global health pharmacopeias.\n\nDRUG 3 NAME: Perindopril\nDRUG 3 BACKGROUND INFORMATION: Perindopril, a potent long-acting angiotensin-converting enzyme (ACE) inhibitor, effectively mitigates hypertensive states, heart failure, and stable coronary artery disease by obstructing angiotensin II synthesis, a critical vasopressor, thereby engendering vasodilation and augmented natriuresis, cumulatively attenuating systemic vascular resistance and volumetric load. The prodrug, perindopril, undergoes hepatic biotransformation to its active moiety, perindoprilat, exerting pharmacological efficacy through increased plasma renin activity and suppressed aldosterone biosynthesis, resulting in enhanced sodium excretion. Administered as perindopril arginine/amlodipine or perindopril erbumine, these formulations remain bioequivalent yet necessitate dosage adjustments for optimal equipotent dosing. Due to teratogenic potential, its usage is contraindicated during gestation, and hypersensitivity reactions alongside adverse events such as persistent cough, cephalalgia, vertigo, gastrointestinal disturbances represent common tolerability issues.\n\nDRUG 1 - DRUG 2 INTERACTION TRIPLE (subject-predicate-object): phenytoin-haemorrhage intracranial-Dapsone\nDRUG 2 - DRUG 3 INTERACTION TRIPLE (subject-predicate-object): Dapsone-acute kidney failure-Perindopril\n"}]}}
